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P R O C E E D I N G S
(10:00 a.m.) 
WELCOME AND OPENING COMMENTS
DR. PAUL ZIEMER, CHAIR
DR. ZIEMER:  Let’s take an official roll call again 
here. I’m going to call the meeting to order.  
This is Ziemer, and I’m in Cincinnati actually.  
We’re having an orientation session today for 
three new Board members who will be joining us 
after our January meeting, newly appointed by 
the White House.  Let me pause here for a 
moment and make sure that Ray Green, Ray, are 
you on board and recording? 
COURT REPORTER:  Yes, sir. 
DR. ZIEMER:  Thank you. 
The new members that are here with us today in 
Cincinnati are Brad Clawson who’s from Idaho INEL, 
John Poston who’s from Texas A&M, and Jim Lockey 
who’s here locally at the University of Cincinnati 
Medical School, I believe it is.  So we welcome 
them here. They’re basically observing today in 
part of their orientation.  Also present here, 
Larry Elliott and Jim Neton are here and Lew Wade 





























DR. WADE:  Roy DeHart. 

DR. DeHART:  Present. 

DR. WADE:  Robert Presley. 

MR. PRESLEY:  Here. 

DR. WADE:  Paul Ziemer. 

DR. ZIEMER:  Here. 

DR. WADE:  Mike Gibson. 

MR. GIBSON:  Here. 

DR. WADE:  Gen Roessler. 

DR. ROESSLER:  Here. 

DR. WADE:  Wanda Munn. 

MS. MUNN:  Here. 

DR. WADE:  Henry Anderson. 

DR. ANDERSON:  Here. 

DR. WADE:  Jim Melius. 

DR. MELIUS:  Here. 

DR. WADE:  Mark Griffon. 

MR. GRIFFON:  Here. 
































DR. WADE:  And Leon. 

DR. ZIEMER:  Leon Owens is not on at the moment. 

DR. WADE:  I make it that we have nine Board 

members present. We have a quorum.  We can conduct 

business if we need to. 

DR. ZIEMER:  Also, there are a number of members of 

the public that are on.  We don’t need to take a 

roll, but I just make sure that everybody’s aware 

that this is an open meeting and members of the 

public are, have been invited to observe by phone 

as it were, and I believe there are a number of 

those aboard also this morning.  We do ask that, we 

always have trouble with these telephone 

conferences in terms of background noise and so on.  

And in some cases if you’re simply listening, you 

may want to push the mute button on your phone to 

cut out background noises that would come in from 

your phone, particularly if there’s other 

conversations going on in your office or wherever 

you’re located. With that let me make sure that 

everybody has a copy of the agenda.  Is there 

anyone that did not get a copy of the agenda?  And 































that the agenda is on the website that’s available 
to you there. Dr. Wade is going to make a couple 
of remarks. I want to mention to you that this 
particular meeting of the Board was primarily 
intended to bring us up to speed on the actions of 
our working groups that have been working since the 
last meeting and in preparation for our full face­
to-face meeting later this month. So we largely 
will be having discussions and hearing reports.  
The actual actions will probably be minimal though 
there are a couple of actions recommended by at 
least Mark’s working group.  Lew, you have some 
introductory remarks.   
DR. WADE:  Yeah, just a couple of things.  First of 
all, let me thank you on behalf of the Secretary 
and the CDC Director and the NIOSH Director for 
making this time available.  I would like to talk 
just a little bit about we are in transition on the 
Board and as Dr. Ziemer mentioned, we have three 
new members who are with us today formally involved 
in orientation and a transition onto the Board.  
The way we intend to work this is at this meeting 
we do have a quorum present of the former Board 
members, and we can conduct business.  If there are 





























meeting. There’s also our expectation they will 
not be voting at the end of January meeting in Oak 
Ridge. Any meetings after that the new members 
will be voting and the old, the members rotating 
off will be, will no longer be voting and not 
present as Board members.  They can certainly be 
present as members of the public. Relative to 
conflict of interest, let me talk a little bit, on 
our agenda today as you would look at it, we will 
be talking about two site profiles, Bethlehem Steel 
and Y-12. I’ll remind you of the Board’s policy on 
conflict of interest.  If a Board member is 
conflicted on either of those sites, since we are 
talking about site profile work, the Board member 
would be allowed to participate fully in the 
discussion. They can stay at the table, but they 
would not participate in any votes.  They would 
have to recuse themselves from voting if they are 
conflicted. And again, at this meeting the only 
two we’ll be talking about are Bethlehem and Y-12.  
I would like to -- some thanks are in order. Two 
working groups have been working very hard, one 
chaired by Dr. Melius and one chaired by Mark 
Griffon. I thank all of the members of those 
































thank Dr. Melius for his leadership and the writing 
that he’s done.  And you’ll be hearing his report 
today. But I would be remiss if I didn’t single 
out Mark Griffon for special thanks on the part of 
the government. Mark’s efforts have been 
considerable. The quality of his work has been 
worthy of note. In my time dealing with boards 
like this, I’ve never seen anyone make the 
contribution that Mark has made, so I think it’s 
important that for the record we thank Mark. 
DR. ZIEMER:  Thank you, Lew, and certainly Mark and 
Jim, on behalf of the Board we echo those same 
thoughts. We really appreciate the input and 
leadership that you both have provided in these 
areas. 
REPORT FROM WORKING GROUP ON 
BETHLEHEM STEEL SITE PROFILE
MR. MARK GRIFFON, GROUP CHAIR
Let’s begin then with the work on the Bethlehem 
site profile, and I might also mention just so the 
members are aware also of Ed Walker who’s, I think 
all the Board members know from the Bethlehem site, 
is on the phone today as well, and we welcome Ed 
with us this morning. 
Mark, your group’s been working with the 




























issues relative to the site profile, so why don’t 
you lead us through your report and your 
recommendations, and we’ll have an opportunity for 
any discussion that any of the Board members wish 
to have. 
MR. GRIFFON:  Yeah, I think we, I want to start 
with making sure that people got the materials.  
mean, I sent a one-page document which is basically 
a recommendation from the work group for a full 
Board motion. So it’s --
DR. ZIEMER:  Yeah, let’s make sure that everyone 
got that. That was -- it went out by e-mail.  The 
e-mail was dated actually, Mark, I believe -- no -- 
MR. GRIFFON:  The day before. 
DR. ZIEMER:  -- yesterday or the day before.  It 
went out over the weekend.  And then a recommended 
action item, and then also a summary matrix was 
also sent out. 
MR. GRIFFON:  Right, and we’ve been, if you have 
those materials, we’ve been, the work group and the 
full Board have seen this matrix before.  And we’ve 
been working on an ongoing basis with SC&A and 
NIOSH to come to resolution on these six findings.  






























phone call, November 28th, I believe that was.  We 
had a phone call, and you can see the Board actions 
on the right-hand column of the matrix.  I wasn’t 
planning on going through all of those, but 
basically the sense from our work group was that 
NIOSH’s responses to SC&A’s original six findings 
have now been met in terms of the Bethlehem Steel 
site profile. Based on information we’ve reviewed 
so far that’s what we’ve come to that conclusion.  
Now, it also should be pointed out that in some of 
the Board actions there’s an ongoing action 
recommended for NIOSH to work on a general policy 
in certain areas, such as, I believe, that comes up 
in the oronasal breathing issue, finding number 
three, and I think finding number four as well.  
You can look at, some of these issues we believe, 
finding three, four and five especially I’m looking 
at, several of these issues, as we were going 
through these we realized that these are going to 
be recurring issues on many sites potentially.  And 
therefore, NIOSH certainly wants to handle these in 
a consistent manner; and therefore, should develop 
some more generic guidelines on how to handle these 
issues. And we should also review those. 




























site-specific actions we feel have been addressed 
in the resolution process thus far. And therefore, 
we bring forward this motion which I wrote this as 
a recommendation to the full Board, but the motion 
is written in terms of of the Board.  So I don’t 
know if we want to have a discussion before the 
motion or how --
DR. ZIEMER:  If you are prepared to make this, 
actually, this comes as a product of the work group 
and constitutes a motion.  It doesn’t require a 
second. So I’ll simply declare that the motion is 
open for discussion.  In that context we can 
discuss the matrix or any related item. 
As you discuss this, identify who you are for Ray 
Green’s reporting purposes. 
MS. MUNN:  Mark, this is Wanda.  I haven’t had a 
chance to check my e-mail this morning so I don’t 
know whether you did put together your specific 
motion incorporating Bob’s comment or not. 
MR. GRIFFON:  Yeah, I did. Mike also sent a 
response to that, Wanda, and the nature of Bob’s 
modifications for those on the call was to change 
the first part of the motion to read that it is the 




























based on this information -- and I just thought if 

we’re going to -- I can go either way with this I 

guess. But I thought if it’s written in terms of a 

motion that the top of my letter that I sent out to 

everyone says that this is a motion from the 

working group for the entire Board to vote on is 

the way I was kind of writing it. So I wrote it in 

terms of the Board, where mine says it is the 

opinion of the Board. 

DR. ZIEMER:  Let me simply make a ruling on this 

that will help move us along.  Whatever is adopted 

would be the adopted as a motion of the Board.  And 

Mark, I’m interpreting your group as recommending 

some wording for the Board to adopt.  But we 

understand that this is the, the working group’s 

recommendation is that the following statement be 





MR. GRIFFON:  Is that clear, Wanda?  Then so we’re 

going with the first draft that I -- 

MS. MUNN:  Yes. 

DR. ZIEMER:  But whatever the, if the Board chooses 

to pass this motion, then it would read as an 































DR. ANDERSON:  It’s pretty short.  If others don’t 
have it, maybe you could just read it. 
DR. ZIEMER:  I will read it as it was distributed 
in case members of the public don’t have it or 
others. It’s, basically, it’s a single sentence 
and here’s how it reads:  “It is the opinion of the 
Board and the Board’s contractor that based on the 
information available at this time, the Bethlehem 
Steel site profile as modified through the comment 
resolution process is acceptable for use in the 
NIOSH dose reconstruction program with the 
understanding that the action items listed in the 
attached matrix will be completed, and that NIOSH 
will track all ongoing action items and provide the 
Board with quarterly updates on each of the six 
items listed in the matrix.”   
And that is the motion.  By implication the 
matrix becomes part of the motion ‘cause it’s 
referred to, and I’m not proposing to read the 
whole matrix here. But the matrix has six 
findings. It has the original, our contractor’s 
findings, NIOSH’s response, and the final 
resolution of those listed as what the Board agrees 
-– the Board’s actions. 





























DR. MELIUS:  Yes, this is Jim Melius.  What I’m a 
little confused about is what happens next.  NIOSH 
will then revise the site profile further or what 
exactly will take place going forward? 
DR. ZIEMER:  I’m going to let Larry or Jim respond 
to that, but let me point out that the generic 
items which are part of findings three, four and 
five which basically are anticipated to be items 
which will show up again in other sites, not 
necessarily the developing of generic guidance is 
for future applications I assume, but that, the 
Bethlehem site’s not dependent on that.  I believe 
that’s correct, but let Jim and Larry... 
MR. ELLIOTT:  There are some general, generally, 
general issues relevant to other sites, and what 
will happen next is we will revise the Bethlehem 
Steel exposure model and any other technical 
information bulletins that we, that are associated 
with these issues.  We’ll bring those back to the 
Board to show them how we’ve made those revisions.  
We will proceed with doing dose reconstructions 
under the intent of these changes. 
DR. ZIEMER:  Let me ask the question.  These would 
be the sort of generic models which would then be 



























MR. ELLIOTT:  As appropriate. 
DR. ZIEMER:  -- as appropriate. 
 Jim Melius, does that answer your question? 
DR. MELIUS:  Yeah, that helps. Assuming -- maybe I 
shouldn’t assume -- any questions, sir, what’s 

roughly the time frame for this? 

DR. ZIEMER:  Jim Neton’s going to answer. 

DR. NETON:  Yeah, this is Jim Neton.  Are you 

speaking relative to the specific changes we’re 

making at Bethlehem Steel or the more overarching 

issues raised in findings three, four and five? 

DR. MELIUS:  I would think the, both information if 

you’ve thought about it.  I don’t know. 

DR. NETON:  I think that we’ve come to a pretty 

good agreement as to what the path forward is for 

the Bethlehem Steel issues, and I would hope that 

we could get these put to bed fairly quickly, 





I would like to be able to resolve those, you 
know, modify the site profile and incorporate the, 
our actions as we indicated here.  But the longer 































DR. MELIUS:  Okay, good. I was just, Mark’s motion 

that spoke to the idea of quarterly updates, and I 

was just trying to separate out -- 

MR. ELLIOTT:  It would be our interest to bring 





DR. MELIUS:  And I understand, I’m just trying to 

understand what was happening. 

DR. NETON:  I would hope that we would have the 

disposition well before the quarter is out. 

DR. ZIEMER:  Other questions or comments? 

MR. WALKER:  Yes, Dr. Neton, this is Eddie Walker.  

Am I allowed to comment on that? 

DR. ZIEMER:  I think we’ll allow Ed to comment 

since he’s been involved in the process. 
Ed, please go ahead. 
MR. WALKER:  I received a letter from Mr. Elliott 
on the 30th, 12/30/05, that was in response to a 
letter that I had faxed him or e-mailed him back in 
September 20th, 2005. I finally got my response.  




























sent out by e-mail, but I didn’t get that.  It 
didn’t come through. 
And it didn’t give me much time to prepare, but 
I do have a considerable amount of issues that I 
really think should be looked at.  I think they’re 
important, and I think if we’re talking about 
having worker input, I think it’s very important 
that these be gone over before any final decision 
is made. 
DR. ZIEMER:  Ed, can you transmit those to NIOSH or 
have you already or... 
MR. WALKER:  Well, I was trying to but with the 
time that I had, I didn’t have quite enough time.  
I hope to have them finished within a day, possibly 
get them out tomorrow.  There’s quite a few issues 
on the whole program as I see it from the worker 
input. 
DR. ZIEMER:  Well, if you would transmit those to 
Larry Elliott, and I think the Board would 
appreciate getting copies of those as well because 
if we had those, thank you, that would be useful. 
MR. WALKER:  Okay. 
DR. ZIEMER:  I don’t know that that will affect 





























suggesting it might, Ed? Is that --
MR. WALKER:  I would certainly think so.  From 
what, you know, from what I’ve put together.  I’ve 
gone back over all the findings.  A lot of the 
items are from the findings of the facts that 
conflict with some of the stuff that I’ve been told 
as we’ve been going along.  And it’s just a black­
and-white type thing. 
DR. ZIEMER:  Well, let me also comment to the Board 
that even if the Board passes this item, if there 
are issues that arise, I think if things are not, 
this is not the situation that closes the doors to 
future changes. I mean, the nature of how we do 
site profiles is with new information we always 
have the opportunity to go back and readjust if 
needed. So certainly that input can be looked at 
and it’s, if this impacts on this that can be 
handled. 
MR. ELLIOTT:  We certainly welcome any comment, any 
input. We’ve welcomed it in the past.  I think 
clearly one of these six issues that we have on, 
that have been presented in this matrix speaking to 
us following up with former workers about an issue 
on the cobbles, and we would certainly welcome any 



























follow up on. 
DR. ZIEMER:  Thank you, Ed. 
Board members, any other comment or questions? 
MR. GRIFFON:  Paul, one other thing.  You forwarded 
a letter yesterday or the day before.  It’s from 
Clinton’s staff, I believe. 
DR. ZIEMER:  I think the letter I forwarded was the 
letter from Hillary Clinton.  Is that the one? 
MR. GRIFFON:  Right. Does that have any bearing on 
this discussion or --
DR. ZIEMER:  Well, it deals with Bethlehem Steel, 
and I was going to handle that separately after we 
discussed this. I don’t know that it necessarily 
impacts on this action.  Do you feel that it does? 
MR. GRIFFON:  I’m not sure, and I just glanced at 
it. And I wasn’t sure if we ever received it 
before, but I didn’t remember receiving it before. 
DR. ZIEMER:  No, I hadn’t distributed it.  I got it 
after our last, you know, we had a number of 
letters from the New York delegation which we 
responded to after the last meeting.  And then I 
got the Clinton letter, I thought that probably a 




























the Bethlehem Steel situation, but again, under the 
Board’s mandate. I have not responded to this 
until we had a face-to-face meeting.  And in any 
event, it’s similar to letters we’ve received from 
the other members of the New York delegation, 
representatives and senators and -- 
MS. MUNN:  This is Wanda. I didn’t see any new 
items brought forward in Senator Clinton’s letter 
which would require any response other than the 
ones that we have already given. 
DR. ZIEMER:  I was going to suggest that we take 
separate action. The Board needs to authorize the 
Chair to respond to the letter, but if you think 
there’s something in the letter that affects this 
motion, we certainly can deal with that. 
MS. MUNN:  Mark, did you see anything other than 
what was --
MR. GRIFFON:  I just wanted to pause because I must 
admit I’ve been pretty busy with Y-12 this weekend 
so I just glanced at this.  And I just wanted to 
make sure --
DR. ZIEMER:  The content to me looks very similar 
to the other letters that we received from the New 




























response similar to the others but updated with a 
newer --
DR. WADE:  Since it’s been raised -- this is Lew 
Wade, why don’t I just read the letter for the 
record? 
DR. ZIEMER:  Sure. And for the record I think this 
letter goes on the website so, but -- 
DR. WADE:  But just since it’s been raised and the 
context of possibly this vote, let me read the 
letter. It’s addressed to Paul Ziemer, dated 
November 7th, 2005, from Hillary Rodham Clinton. 
“Dear Dr. Ziemer: I am writing in regards to 
your ongoing review of the site profile of the 
Bethlehem Steel facility in Lackawanna, New York.  
I understand that at the October meeting of the 
Advisory Board on Radiation and Worker Health you 
discussed issues raised by Sanford Cohen and 
Associates about the site profile as well as new 
information introduced by Mr. Eddie Walker.  I 
appreciate the Board’s consideration of this new 
information and the Board’s commitment to include 
Mr. Walker in future discussions about the site 
profile. 





























Mr. Walker is further evidence that the Bethlehem 
Steel site profile is faulty and cannot form the 
basis for accurate dose reconstructions.  It is now 
more than five years since the Energy Employees 
Occupational Illness Compensation Act (EEOICPA) was 
signed into law on October 30th, 2000. After 
passage of that act it took more than three years 
for the National Institute of Occupational Safety 
and Health (NIOSH) to issue the first site profile 
for a Bethlehem Steel facility.   
 “The original site profile was flawed, and it 
was subsequently revised in June of 2004, but only 
after an audit of the June 2004 site profile by 
Sanford Cohen & Associates did NIOSH take seriously 
the comments of former workers such as Mr. Walker.  
As a result, NIOSH has made corrections to the site 
profile in the last year.  But as your recent Board 
meeting demonstrates, there are significant 
outstanding questions about the site profile.  In 
addition, relevant information that is not 
reflected in the site profile continues to be 
brought forward. 
“For all of these reasons I strongly believe 
that the only fair course of action is to establish 





























workers, and I have introduced legislation to 
accomplish this goal.  The reason that a special 
exposure cohort is necessary is that the data we 
have at Bethlehem Steel is woefully inadequate.  
There is no personal monitoring information for 
Bethlehem Steel workers.  The small amount of air 
monitoring data that does exist was taken far from 
the rollers where the uranium work took place, and 
the use of surrogate data from the Simonds Saw 
facility ignores important differences between the 
two facilities. 
“It is too late for the federal government to 
meet the promise of ‘timely’ compensation made by 
Congress when EEOICPA was passed in 2000, but there 
is still an opportunity to treat Bethlehem Steel 
workers and their families fairly.  In light of the 
lack of exposure data, the outstanding questions 
about the site profile and the many years that 
claimants have been waiting, I urge you and the 
Advisory Board to act at your next meeting by 
recommending a special exposure cohort for the 
Bethlehem Steel facility.   
“I thank you for your consideration of my views 
on this important matter and look forward to your 




























DR. ZIEMER:  Thank you, Lew. 
That is the letter and as I say, much of it is 
similar to letters that we’ve received from other 
members of the New York delegation.  So I do need 
to respond to it in some manner, and we can 
actually discuss the response after we deal with 
the motion. I think the immediate question was 
does the letter itself impact on the motion? 
And Mark, I think that was basically the 
question you were asking. 
MR. BROEHM:  Dr. Ziemer? 
DR. ZIEMER:  Yes. 
MR. BROEHM:  This is Jason Broehm in the CDC 
Washington office. 

DR. ZIEMER:  Yes, Jason. 

MR. BROEHM:  I just wanted to make sure that you 

had also seen a November 14th letter from Senator 





DR. ZIEMER:  I --

DR. ROESSLER:  The one that was sent out on 






























MR. BROEHM:  It was forwarded by you to all Board 
members. 
DR. ZIEMER:  Oh, okay, I don’t have that letter 
here, and so when you gave a date, I’ve received 
over this past year several letters from Senator 
Schumer so. I think it’s been distributed to the 
Board or was sent to all the Board members. 
Questions or comments now?  We’re still dealing 
with the original motion. 
 (no response) 
DR. ZIEMER:  I’m going to raise a sort of a 
parliamentary question here.  The motion, I’ll ask 
Mark, it says it’s the opinion of the Board and the 
Board’s contractor.  I’m wondering if the Board can 
take an action to express the opinion of our 
contractor. Might we -- and there are contractor 
representatives on the phone, and I don’t know if 
the contractor is authorized to include this.  But 
I was going to suggest if we could say something 
like it is the opinion of the Board based on input 
from our contractor, but I -- Mark is that -- 
MR. GRIFFON:  Yeah, that might be better.  That 
was, the intent was really just to indicate that, 




























resolution process. So I think you’re right.  We 
can’t give their opinion, but based on input from 
the contractor. 
DR. ZIEMER:  Well, I wonder if the working group 
would consider that to be a friendly -- well, the 
Chair shouldn’t be amending the -- does someone 
wish to propose that as a friendly amendment? 
MR. PRESLEY:  This is Bob Presley.  I will, I had 
sent something in to leave that statement out of 
there, but I will be the person to offer that 
friendly amendment. 
DR. ZIEMER:  Okay, the friendly amendment, and I 
think we could put it parenthetically, it is the 
opinion of the Board, parenthesis, based on input 
from the Board’s contractor.  Would that be 
satisfactory, Mark? 
MR. GRIFFON:  Yeah. 
MR. PRESLEY:  That’s satisfactory to me.  This is 
Bob Presley. 
DR. ZIEMER:  Okay, that’s the friendly amendment 
from Bob Presley, agreed to by the mover of the 
motion. 






























DR. ZIEMER:  Okay, Wanda. 
MS. MUNN:  I believe our contractor has agreed to 
all of the items that are listed in the matrix.  
We’ve gone through them rather extensively.  And in 
each case the contractor has agreed to all the 
items that were dropped off of the matrix because 
they were resolved, and has agreed to the 
stipulations that are shown on the matrix.   
This was not just input from the contractor 
that brought us to this point.  It was a rather 
arduous effort with the contractor’s involvement.  
Therefore, I guess if we’re going to, if we’re 
going to say that we cannot speak for the 
contractor, then since the contractor is on record 
as having agreed to all the things that we have 
there, it’s my feeling we should either leave the 
wording that it is the opinion of both the Board 
and the contractor, or we should eliminate the 
contractor comment completely.  Or we should expand 
it further more than just by input from the 
contractor. 
 They haven’t, this has not been casual input is 
the point I’m trying to make.  And anyone who reads 
this statement I would like to have understand very 



























this is the circumstance now, and these have been, 
these actions have been agreed to. 
DR. ZIEMER:  Thank you for that input. 
What do the other Board members feel about it?  
Do you want to leave it as it was? 
In other words, Wanda, from what you said it 
sounds like actually the working group was somewhat 
intentional about including that statement, and it 
has a certain strength of its own. Unless the 
contractor objects, we could certainly leave it in. 
MS. MUNN:  Well, let’s say that the working group 
has discussed this specific point.  And if there is 
objection from the contractor, we have contractor 
personnel on the call here.  Is there an objection? 
DR. WADE:  Is John Mauro on the call? 
DR. MAURO:  Yes, I am. Either way is certainly 
fine with us. 
DR. ZIEMER:  You have no objection to having -- 
DR. MAURO:  Whatever the decision is, whether to 
leave some language in there making reference to 
the contractor or not, that’s certainly, it’s 
appropriate from our perspective either way. 



























should leave it as is. 

MR. GRIFFON:  I guess that was my original thought.  

I agree, Wanda. You’re correct on this. 

DR. ZIEMER:  We’re hearing from Mark, Wanda and 

Mike who are all on the working group that it was 





So Robert, the friendly amendment was not 
sufficiently friendly, I guess.  Do you object to 
withdrawing that? 
MR. PRESLEY:  This is Bob Presley.  I had offered 
up something to the working group about leaving the 
wording totally out, prior.  I can live with it 
either way. 
DR. ZIEMER:  It seems like most of the working 
group thinks it should be in.  Board members, any 
objection to leaving it in as original? 
 (no response) 
DR. ZIEMER:  There appears to be no objection so 
we’re back to the motion as originally presented. 
I noticed, Wanda, in the version you sent out, 
you had asked that it be in parentheses, however. 




























reasons why I said the working group has discussed 
this point. We’ve gone back and forth about it.  
And I am one of those who originally questioned 
whether we could speak for the working group.  And 
then after discussion it was very clear to me the 
working group has been, that the contractor’s been 
part and parcel of everything we’ve done in the 
working group, and they have agreed to this.  So 
there’s no reason why we shouldn’t state that, in 
my view now. 
MR. GRIFFON:  I think most of the discussion we had 
was can we speak for the contractor, not how much 
they weighed in. 
DR. ZIEMER:  Thank you. 
Further discussion. We’re dealing with the 
motion as distributed by Mark.  Board members are 
you ready and comfortable with taking action on 
this motion? 
DR. ROESSLER:  Yes. 
MS. MUNN:  Yes. 
DR. ZIEMER:  Okay, we’re going to do it by roll 
call so if you’re in favor of the motion, say yes.  
If you’re opposed, say no.  If you’re abstaining, 
























DR. WADE:  Dr. DeHart. 

DR. DeHART:  Yes. 

DR. WADE:  Robert Presley. 

MR. PRESLEY:  Yes. 

DR. WADE:  Mike Gibson. 

MR. GIBSON:  Yes. 

DR. WADE:  Gen Roessler. 

DR. ROESSLER:  Yes. 

DR. WADE:  Wanda Munn. 

MS. MUNN:  Yes. 

DR. WADE:  Henry Anderson. 

DR. ANDERSON:  Yes. 

DR. WADE:  Jim Melius. 

DR. MELIUS:  Yes. 

DR. WADE:  Mark Griffon. 

MR. GRIFFON:  Yes. 

DR. WADE:  Leon Owens. 

 (no response) 
DR. WADE:  Richard Espinosa. 



























DR. ZIEMER:  I vote, too. 

DR. WADE:  Let the record show we have not heard 

from Leon Owens or Richard Espinosa. 

 Paul Ziemer. 
DR. ZIEMER:  Yes. 
DR. WADE:  The motion passes. 
DR. ZIEMER:  Thank you very much. 
In connection with Bethlehem Steel, let me now 
raise the issue of responding to the Clinton 
letter. Does the Board wish to have me respond in 
a manner similar to the other letters to the New 
York delegation?  If I did so, I would simply 
update the numbers to, say, the end of December 
rather than the end of October.  But, or do you 
wish to propose that anything else be said? 
DR. DeHART:  This is Roy. I think since the letter 
is very similar, if not identical, I would 
recommend that we respond in kind. 
MR. PRESLEY:  This is Bob Presley.  I agree. 
DR. MELIUS:  This is Jim Melius. I disagree. The 
reason -- I don’t have the other letters here, but 
I have the response to the other letters.  And I 





























different issues, and I just think it would be more 
sort of polite to craft a letter that may have only 
a few changes in it.  But I think the issue of the 
special exposure cohort status at least, was not 
addressed in our responses to the other letter.  
And I would just caution that we look and make sure 
that we’re responding to the points raised in the 
actual letter. 
DR. ZIEMER:  I don’t recall actually whether that 
was or not, Jim. I’ll have to go back and look.  
What I’m going to suggest, if everyone’s agreeable, 
that I draft a letter and have it ready for you to 
review at our full meeting.  I don’t think we want 
to wordsmith this now by phone.  It would simply 
delay things by a couple of weeks.  But I think 
rather than try to go back, I don’t have the other 
letters here with me in Cincinnati, but we could 
get them. But does anyone object to us using the, 
drafting a letter, and I would distribute it in 
advance of the meeting and then you’d have an 
opportunity to look at it?  I’d take into 
consideration the comments on SEC and any other 
specific things, otherwise I think it probably is 
quite similar. 




























Broehm, are you with us? 

MR. BROEHM:  I am. 

DR. WADE:  Do you have the letter you referenced 

from Senator Schumer? 

MR. BROEHM:  I do have it here. 

DR. WADE:  Could you read that letter just so, I 

want to be sure that if that letter has been 

responded to, we acknowledge it.  If it’s not, that 

Dr. Ziemer also draft a response to that. 

MR. BROEHM:  It’s a letter from Senator Charles 

Schumer from New York dated November 14th, 2005, 

addressed to Board Chair, Dr. Ziemer. 

“Dear Dr. Ziemer: First of all, thank you for 
recommending to the Secretary of Health and Human 
Services that a special exposure cohort be granted 
to the former workers of Linde Ceramics.  The 
Board’s decision to apply the special exposure 
cohort to long-suffering Linde Ceramics’ workers is 
just, enlightened and humane.   
“Prompt approval of this approach will provide 
former workers who were exposed to harmful and even 
lethal doses of radiation while they toiled in 
America’s nuclear weapons program long overdue 





























Leavitt, urging his final approval of this 
recommendation. 
 “However, the intelligence of the Linde 
decision only underscores the festering injustice 
that continues to be visited upon the former 
workers of Bethlehem Steel.  Those workers have 
waited far too long for the opportunity to seek 
justice for the injuries they suffered while 
building the arsenal of weapons that underpinned 
our nation’s security during the Cold War and 
beyond. 
“Therefore, today I am also urging the Advisory 
Board on Radiation and Worker Health also grant a 
special exposure cohort to Bethlehem Steel workers.  
As you know the Linde decision was made using a 42 
CFR, Chapter 1, Subpart (c), Section 83.6 which 
allows NIOSH to grant a special exposure cohort to 
workers if there is ‘insufficient information to 
estimate the radiation doses of the claimant with 
sufficient accuracy.’  I believe that this clause 
is also applicable to the former workers at 
Bethlehem Steel. 
 “Currently, data from the era when Bethlehem 
Steel workers were exposed is incomplete.  In an 





























NIOSH is using air sample data from Simonds Saw and 
Steel. It is very possible that an accurate dose 
reconstruction model cannot be formulated, a 
situation that will exacerbate delay.  Simply put, 
further delay in granting compensation to former 
Bethlehem Steel workers is unconscionable.  A 
better, simpler, faster and infinitely more just 
approach is to grant a special exposure cohort to 
these workers as soon as possible, perhaps at the 
next meeting of the Board. 
 “Secondly, I ask you to hold the next full 
meeting of the Board scheduled for January 25th 
through 27th, 2005 (sic), now scheduled to be held 
in Knoxville, Tennessee, in Buffalo, New York.  I 
believe all of the former Cold War era nuclear 
workers have the right to witness actions taken on 
the site profile and to directly participate in the 
public comments session. 
“Despite having one of the greatest 
concentrations of facilities involved in nuclear 
weapons production and related activities, western 
New York continues to be severely underserved by 
the Energy Employees Occupational Illness 
Compensation Program.  During the Cold War, New 




























sites and DOE clean-up facilities. In the eight 
counties of western New York there are 14 
facilities that participated in the manufacture of 
America’s nuclear arsenal.  The time is now to 
allow these beleaguered Cold War soldiers to 
directly participate in the program that was 
designed to provide the justice and compensation 
their sacrifice merits. 
“If you have any questions, please do not 
hesitate to contact me.  I can be reached at 2-0-2­
2-2-4-6-5-4-2. Sincerely, Charles Schumer, United 
States Senator.” 
DR. WADE:  Thank you. 
 For the record, I think that letter has been 
distributed to Board members. 
DR. ZIEMER:  I believe that’s correct.  So both of 
these letters will require a response, and both of 
them reference the issue of a special exposure 
cohort for Bethlehem Steel. So that would require 
a specific, or a somewhat different response than 
the original letters did. 
So what I will propose then is drafting both of 
these letters for Board review.  Now, I don’t know, 




























can do anything about that at this time since that 
Oak Ridge meeting’s been established for quite some 
period there, right, Lew? 
DR. WADE:  Correct. I don’t think that’s an 
option. 





MR. GIBSON:  Dr. Ziemer? 

DR. ZIEMER:  Yes. 

MR. GIBSON:  This is Mike Gibson.  Since, as far as 

I know, we haven’t made our travel plans or 
anything else other than maybe booking the motel in 
Oak Ridge, or not -- yeah, Oak Ridge, and I 
understand that we’re not going to be able to 
deliberate the Oak Ridge or the Y-12 SEC petition, 
is it, in fact, too late to try to get a motel in 
Buffalo and change our meeting place? 
DR. WADE:  This is Lew Wade.  I think logistically, 
Mike, it could be done.  I think that we will have 
substantial discussions in Oak Ridge on the Y-12 
site profile. Again, the issue of a special 
exposure cohort really needs to be sorted.  There 
is no such proposal on our table; and therefore, it 




























plan to meet in Oak Ridge in the end of January. 

DR. ZIEMER:  Both of these letters indicate that 

some legislation has been or is being introduced by 

both individuals to designate Bethlehem Steel as an 

SEC. We don’t have a petition I don’t believe. 

MR. ELLIOTT:  No, sir. This is Larry Elliott.  We 

do not have a petition. 

MR. GIBSON:  I’m sorry; I misspoke.  I meant the 

site profile was on the agenda I believe. 

DR. ZIEMER:  Right, right. 

DR. ROESSLER:  This is Gen Roessler.  Paul, on the 

letter, I have one in my file that you responded to 





DR. ZIEMER:  Yes, there was an earlier letter that 

we had at our last meeting.  There were several 

letters from different ones in the New York 

delegation, and we approved a response which 

basically provided them information on the awards 

already made at Bethlehem Steel and the status of 





Basically, it was an information letter.  And 



























seemed to imply that no one at Bethlehem Steel had 
been, no cases had been dealt with or something to 
that effect. And a large number have been already, 
doses have been reconstructed, and actually quite a 
large number of awards were actually made.  But it 
was simply an information letter. 
DR. ROESSLER:  Okay, I think I --
DR. ZIEMER:  These two came in after our Board 
meeting, and therefore, have not been responded to. 
Yeah, go ahead. 
DR. ROESSLER:  Thank you. 
DR. WADE:  I just think I would -- this is Lew.  
I’d be pleased to hear from the Board as to its 

desires on the location of the next meeting.  I 

just stated my view. 

DR. ZIEMER:  Any other comments? 

MR. WALKER:  Dr. Ziemer? 

DR. ZIEMER:  Yes. 

MR. WALKER:  Eddie Walker. I certainly obviously 

would like to see it in Buffalo being that I 

understand that Bethlehem Steel was the largest AWE 

facility in the country, and we’re the ones that we 





























site profile and technical based document, that it 
would only be fair to the group up here that it be 
discussed and a settlement made up here of some 
sort or a decision made up here.  So I think 
Senator Schumer asking for it to be held in Buffalo 
is certainly a reasonable request. 
DR. ZIEMER:  Thank you. 
 Other comments, Board members? 
MR. PRESLEY:  This is Bob Presley. 
DR. ZIEMER:  Bob. 
MR. PRESLEY:  As I understand it right now, we do 
not have any action that can be taken in Buffalo 
until we get an SEC petition from them.  Is that 
correct? 
DR. ZIEMER:  I believe that’s the case.  Is that --
let me defer here. 
MR. ELLIOTT:  That’s correct. We have no petition 
on Buffalo on the Bethlehem Steel site and with the 
Board’s motion being passed just now , we will, you 
know, make revisions to the site profile, but I 
don’t believe that we have any business relevant to 
Bethlehem Steel for the -- 



























those revisions would not be ready for our next 

meeting anyway. Is that correct? 

DR. NETON:  Right, the --

MS. MUNN:  I think that’s correct. 

MR. PRESLEY:  That’s what I heard him say.  This is 

Bob Presley. I can see -- I hate to say that, but 

I can see no reason right now for changing this 

meeting, and then maybe down the road we schedule 

one for Bethlehem Steel when something comes up. 

DR. ZIEMER:  Other comments? 

MS. MUNN:  This is Wanda. I understand the concern 

that everyone has for timeliness here, but I also 

understand the need for timeliness with respect to 

all of the other sites that are involved.  And we 

do have a basketful of sites.  We are currently 

working on several activities in the Oak Ridge 

area, and Y-12 is taking an incredible amount of 

time and an incredible amount of effort for all of 

the agencies and the contractors involved.  We 

probably need to be at Y-12. 

MR. WALKER:  That burden -- pardon me, Dr. Ziemer? 

DR. ZIEMER:  Yes. 































Steel workers. I thought there was ample time that 
we could have come to a decision by now, but I 
can’t see where Bethlehem Steel, as far as having a 
meeting in Buffalo or down at Y-12, you know, it 
doesn’t make much difference to me except I don’t 
think any final decision should be made outside of 
Buffalo. 
DR. ZIEMER:  Okay, thank you. 
MR. WALKER:  And we have been working on it a 
considerable amount of time, and I know everybody’s 
put a lot of work into it.  But I just feel that we 
should, it should be done up here being that other 
facilities are waiting on our decision on how you 
do your dose reconstruction program. And as far as 
not putting in a special exposure cohort, the 
reason that wasn’t done because our site profile 
was completed, and we were being denied in 2003.   
So what’s the sense of putting it in in 2004 
when you’ve already been denying our claimants and 
judging our claimants whether they get approved or 
disapproved? Why a year later would we put in a 
special exposure cohort when I was told by one of 
the executives that we wouldn’t get it anyway 
because of the dose reconstruction, that they can 




























the purpose of me going through that, of putting 
our group through going through all of that when we 
know we’re going to have a dose reconstruction? 
DR. ZIEMER:  Okay, thank you. 
 Board members, any further discussion on either 
the letters or the siting of the next meeting? 
 (no response) 
DR. ZIEMER:  Just let me make sure that I have some 
kind of consensus or at least agreement.  Are you 
agreed that I should go ahead and develop a 
proposed response to these two letters for action 
at the January meeting?  Any objections to that? 
MS. MUNN:  No, this is Wanda.  I think you should 
do that. My only concern is whether the senators 
will continue to think that this is an additional, 
unnecessary delay. They’re concerned with 
timeliness. But I see no other way that we can do 
it fairly. 
DR. ZIEMER:  Well, I think it’s quite possible, 
sort of off-line that NIOSH and maybe Lew is able 
to keep their staffs apprised of, I think they’re 
aware of our own internal limitations on responding 
to these letters.  So they understand the situation 































can be kept apprised of, you know, the situation in 
that regard. 
MS. MUNN:  I would appreciate your drafting it for, 
on behalf of the Board. 
DR. ZIEMER:  Unless I hear objections, I’ll plan to 
do that. 
At this point it doesn’t appear that we have 
any strong sentiment to move the meeting, so and 
that’s really not an agenda item, but unless the 
Board members wish to make specific motions, I’m 
going to proceed here with the agenda. 
REPORT FROM WORKING GROUP ON
BOARD REVIEW OF SEC PETITIONS
DR. JAMES MELIUS, GROUP CHAIR
Our next item on the agenda is the report of 
the working group on SEC petitions, and Dr. Melius 
has chaired that working group, and Jim if you 
would -- let me make sure everybody has a copy of 
Jim’s draft document.  It’s called “Report of the 
Working Group on Special Exposure Cohort Petition 
Review”. It’s a draft dated December 29th . Jim, 
thanks for putting the date on that. 
DR. MELIUS:  I figured it would make it easier -- 
DR. ZIEMER:  Right, we always have these problems 





























you’ll proceed and present, walk us through that 
and any comments you wish to make. 
DR. MELIUS:  It just indicates that the draft dated 
12/29/05 does not incorporate all of the comments 
from other working numbers.  Paul has actually sent 
me some comments, and Mark has, that are not yet 
incorporated into the draft.  And Roy was also 
looking over it, and I think, will be sending some 
comments. So I think everything can be blamed on 
me and probably on the transcript because I did go 
over, try to reference some of the stuff back to 
the transcript at the time. 
DR. ZIEMER:  Jim, before you just take us through 
that, let me point out that I don’t think we need 
to necessarily take action on this today.  This is 
basically an information report for the Board, 
solicitation of additional input perhaps with the 
opportunity to update the draft and maybe come to 
closure at the next meeting or later depending on 
how we progress. Is that, was that your 
understanding as well? 
DR. MELIUS:  Correct, yeah. What I will just try 
to do is sort of walk through the process 
(inaudible) the report, but leave it open for 




























raising comments from both Board members as well as 
others. And we can then incorporate and probably 
produce another draft in time for the next Board 
meeting in a few weeks. 
DR. ZIEMER:  Okay, thanks, proceed. 
DR. MELIUS:  There was a meeting held in mid-
November of the work group.  We’ve had, at that one 
meeting, members of the work group were myself, Roy 
DeHart, Mark and Paul.  Also attending the meeting 
in Cincinnati was Lew Wade, Larry Elliott, Jim 
Neton, Stu Hinnefeld and a number of other NIOSH 
staff members, and I believe Brad Clawson also sat 
in for much of the meeting.  
And the purpose as we discussed at our last 
meeting was sort of to try to develop a document 
and a procedure and some criteria that would help 
both NIOSH and the Board in evaluating special 
exposure cohort petitions.  And in doing that we 
determined that we would not, we would use, develop 
this document in the context of the current 
regulations, and we would not try to question or 
change or propose changes to those regulations.   
So some of us would be, want to do that or 





























This was developed within the context of the 
current regulations to that.  And so really we’re 
focusing on, you know, is the criteria of 
sufficient accuracy and so forth and NIOSH’s 
current methods. 
We identified a number of key points or what we 
labeled there the second page of this is “Key 
Considerations for Board Review”. One was that 
these petitions needed to be reviewed and evaluated 
in a timely fashion. So what we, in that our 
Board’s evaluation of NIOSH’s evaluation or Board’s 
review of NIOSH’s evaluation of an SEC petition 
also needed to be able to be completed in a timely 
fashion. And so we needed to sort of stay focused 
and there’s a number of considerations that came up 
there. 
We obviously were concerned that the evaluation 
and our review of that evaluation should consider, 
you know, should the fairness of our actions.  Was 
this consistent with what was being done at other 
sites, and were we treating everybody potentially 
within the cohort in the same manner. 
It also needed to be understandable or 
comprehensible to those involved. And that in 





























complicated these sources of information can be and 
how much uncertainties there are. 
And then as I mentioned, they needed to be 
consistent, we need to be consistent both within 
sort of evaluating a petition from a site, and 
treat everybody at that site fairly, but also we 
need to maintain consistency from site to site in 
evaluating petitions. 
We also then focused on sort of the scope of 
the review recognizing that each petition was 
different, every site was different, and we could 
develop some general criteria, several steps for 
evaluation but again recognizing that these would 
have to be modified going from site to site, and 
even petition to petition within a site, so would 
do that. 
One of the key areas that we focused on because 
it had become a area of concern, and we’d spent a 
lot of time on it dealing with Iowa, Mallinckrodt 
and SEC evaluations was the credibility and 
validity of the datasets that were being under 
consideration. And so in our evaluation, NIOSH’s 
evaluation and our, the Board’s review of the 
evaluation, we thought that we needed to sort of 





























would, type of criteria that we would be looking at 
in evaluating the credibility and validity of the 
datasets. 
I think one key concept is that we wanted NIOSH 
to be able to hone in on what were the important or 
key datasets that in a sense would be key for 
making a determination of a special exposure 
cohort. If they weren’t, those sources were, the 
particular exposures were not going to make a 
significant contribution to a person’s overall 
exposure, you know, a person who worked at that 
site, their overall exposure, we didn’t need to 
spend as much time. 
But I think our experience has been in both 
Iowa and Mallinckrodt was that there are certain 
key sets of data that were going to be critical for 
evaluation of people’s exposure at that site, and 
those were the ones that we needed to focus on.  
And I think also as we found, I think, in 
Mallinckrodt that it may take some time for NIOSH 
to figure out what are the key, critical datasets. 
So I’ll describe a number of criteria or areas 
that need to be focused on in looking at the 
datasets. One was the pedigree of the data.  





























being used to monitor exposure.  Whether it was 
either external or internal monitoring.  What was 
the relation of that dataset or information in that 
dataset to other sources of information about the 
site, about the (inaudible) to other sources of 
exposure data from that site.  And finally, NIOSH 
needs also to be looking at the internal 
consistency of that data. 
 And then another, I think, key concept was the 
representativeness of the data.  What areas of the 
facility were represented in that dataset so that, 
did it include all the relevant areas where people 
were exposed? The time period of that dataset were 
critical. And particularly as we tended to look at 
particular time periods, sort of the border or the 
margins of those datasets, exposure datasets, 
become important where they shift to a more robust 
form of exposure monitoring.  I think we spent a 
lot of time trying to figure out how do you 
extrapolate from one set to another, one time 
period to another. 
The types of workers in processes covered by 
the exposure dataset were important.  And again, 
one concept here was making sure that all the key 





























are well-covered by that exposure dataset.  That we 
needed to, it may be very good for one group of 
workers, but could conceivably be a very poor 
characterization of the exposures for another set 
of workers. 
And I think that sort of flows into sort of 
datasets and subsets of that data in terms of what 
areas, geographic areas might be covered, what 
groups of workers are covered.  And I think we’ve 
come up with sort of a set of key questions that 
need to be evaluated there. 
Then we also talked about ways that NIOSH can 
demonstrate the feasibility and sufficient accuracy 
of that. You know, what did the evaluation of a 
special exposure cohort, what information needed to 
be presented to the Board in a way that would help 
us come to a decision or come to making our 
recommendation. Some of that was what was feasible 
to do, plausible in terms of being able to do the 
evaluation, but the timeliness of the overall 
effort, NIOSH has a time period put on them for 
evaluating petitions. 
The Board needed to be responsive to that.  We 
needed to be able to focus on the data at hand at 





























work done on it in order to be able to do 
individual dose reconstructions, that needed to be 
able to be accomplished within a reasonable time 
period. We had to also void -- disburse the 
treatment of different groups of claimants to that. 
And finally, I think we agreed that in, similar 
to how we’ve done in the most recent petition 
evaluations, I believe at Mallinckrodt, that sample 
or representative dose reconstructions were a 
useful way of demonstrating, of NIOSH demonstrating 
to the Board that there are methods that might be 
proposed if they believe it’s feasible to do 
individual dose reconstruction, that that would be, 
that was a good way of demonstrating that to the 
Board, and the Board evaluating NIOSH’s plan. 
We also proposed, talked about some procedural 
changes to the way that throughout the process.  
One was that NIOSH in presenting to us their 
evaluation plan, that at some point this plan 
becomes a little bit more detailed than what’s 
being developed now.  Right now, NIOSH because 
really puts out a plan before they really had much 
of an opportunity to explore the data and develop a 
specific and comprehensive plan for how they’re 






























Like we were looking for a, it may be somewhat 
later in the process, a more detailed plan thinking 
that that would help the Board focus on how it 
would need to do to review this petition or this 
evaluation of the petition as well as NIOSH in 
going forward. And also, I think as we’ve 
discovered in doing the past few SEC petition 
evaluations was that the review of the site 
profile, or at least the parts of the site profile 
that are relevant to the petition were extremely 
useful in being able, the Board being able to 
evaluate and review NIOSH’s evaluation of that SEC 
petition. 
So that’s a thumbnail sketch of the summary of 
a three-hour meeting.  I believe the transcript of 
our discussions and deliberations is found on the 
website that may contain more detail.  There are 
certainly some things that I think that are left, 
that haven’t been sort of fleshed out in this.  I 
think we were trying to give time for people to 
react. 
But it may very well be that either as part of 
this work group plan or as part of some later Board 





























to more fully develop some of these criteria that, 
at least critical criteria that keep coming up over 
and over again in our SEC petition evaluations.  
What is, what do we mean by feasibility, 
representativeness and issues like that that we may 
want to spend more time on. 
I think it’s fair to say, and I’ll let Larry or 
Jim or Lew, whatever, that even though this was a 
work group of the Board, there was significant 
input from NIOSH at that, a really good exchange so 
I think we’re hoping that our final set of 
recommendations is something that will help NIOSH 
in terms of how it evaluates SEC petitions.  And in 
turn, might just focus for the Board in our review 
of those evaluations. 
DR. ZIEMER:  Jim, thanks for leading us through 
that. There are some comments here from Larry 
Elliott first of all. 
MR. ELLIOTT:  Jim, I think you did an excellent job 
of giving us an overview of the discussion that was 
held. I think it was a very valuable discussion.  
I certainly appreciated hearing the thoughts and 
comments of the working group, and we tried to be, 
from NIOSH’s side of the table, very contributory 




























I think it’s clear to us that while we may have 
been doing some of these things that are, that you 
identified in this document and from our 
discussion, we weren’t doing them as openly and as 
transparently as we should be.  And we certainly 
take note of that and we’ll work and strive harder 
to show how we proceed with our evaluations of 
these petitions. 
I think it was very helpful to us to have the 
discussion about sufficient accuracy and 
feasibility and representativeness of data, and we 
look forward to continuing this discussion.  I 
would offer that, you know, I think a lot of these 
considerations are being factored now into how we 
proceed in developing our evaluations of SEC 
petitions, how we proceed in our review of site 
profiles. And we’re taking this all to heart as we 
move forward. 
DR. ZIEMER:  Thank you, Larry. 
DR. MELIUS:  This is Jim Melius. 
DR. ZIEMER:  Jim, go ahead. 
DR. MELIUS:  I think it’s also important that I 
think also we as a Board, and I’ll speak for myself 





























don’t think we’re always being as consistent and 
careful in terms of how we were evaluating your 
evaluations or reviewing the evaluations produced 
at NIOSH. 
I think we’re all sort of searching and trying 
to find what would be the best way so we weren’t 
always asking the questions at the first meeting.  
And maybe the third meeting or whatever, the third 
time something came up that we’d say, no, let’s 
look at this. Or we’d have this question or that 
question. 
And I think what we’re both trying to look for 
is, both the Board and NIOSH, is a way, sort of a 
path forward that is more efficient so we don’t end 
up on some of these, spending a lot of time or a 
lot of meetings trying to go over territory that’s 
not really, turns out not to be very helpful, and 
so in the same time provides an overall a fair and 
sound review of these petitions.  So hopefully what 
we’re trying to achieve here is something that 
would help and work for both of us in this process.  
So I don’t believe it’s trying to be critical of 
what NIOSH has done or not done.  I think it’s been 
sort of a, whether it’s fault, it’s mutual.  And I 




























that we’ve had some experience dealing with these 
evaluations. 
MR. ELLIOTT:  Jim, I agree, and I think it’s going 
to lead us to a more efficient operation.  We’re 
going to be able to handle these petitions more in 
their reviews, their evaluations and your review of 
that in a more efficient way than we have. 
DR. ZIEMER:  Yeah, and Lew has some comments here 
as well. Lew, go ahead. 
DR. WADE:  I have no comments about the excellent 
work product, but just to remind the Board of a 
conundrum that we face and will continue to face.  
That is, once a petition is qualified, NIOSH has 
180 days to put a petition evaluation report before 
the Board. As this piece of work points out in 
several locations, particularly the last two 
sections of petition evaluation and site profile 
review. 
Quite often during that period there is very 
active work going on in terms of site profile 
review and resolution.  This creates a problem for 
all of us. I think what this document begins to 
ask NIOSH to do is to -- and I’ll read from it.  





























delineate the planned scope of their evaluation 
including the actual steps they plan during the SEC 
evaluation, this will help to facilitate the 
planning and preparation to the necessary schedule 
of meetings, conference calls, et cetera.”   
So there is an understanding here that it’s 
quite possible that while NIOSH might put out an 
initial evaluation report, that evaluation report 
might have to delineate some specific actions that 
are planned and underway.  I think it’s also 
important that the message of this report and it’s 
-- I read from the last element, number two site 
profile review. “Whenever possible the Board’s 
review of the site profile for the site where an 
SEC petition is being considered, should precede 
the SEC evaluation review.”  It’s a lesson we 
learned at Mallinckrodt.  I think it’s a lesson we 
need to take to heart. 
I would like to talk just a bit about Y-12.  
We’re actively involved in now discussions of the 
Y-12 site profile. It appears to us at NIOSH that 
we will not be prepared to discuss the SEC petition 
to closure at the meeting at the end of January 





























So, you might have heard it in other locations.  
It is, therefore, our position that we will not 
take up the SEC petition for Y-12 at the end of 
January meeting. We will delay it as we continue 
to work on the petition evaluation issues. 
MR. ELLIOTT:  And I would offer that have treated, 
there were three petitions on Y-12, all three were 
merged together. And we treated two of the three 
fully and one of the three partially.  And we have 
the remainder years that were proposed in that 
petition, 1948 to 1957, under current evaluation.  
That’s why it’s critical in our minds for us to 
resolve the issues around a site profile and answer 
those questions on those years. 
DR. ZIEMER:  Thank you for those comments. 
 Board members now a couple items here.  I think 
Jim is really soliciting your comments on the 
draft, correct, Jim, so that before our next 
meeting we can consider and include the appropriate 
comments. 
And then the other thing that we would like to 
do today, the Chair would like to do is, if any 
Board members believe that there are major concepts 




























overlooked by this work group, we need to identify 
what those are or if there’s any significant flaws 
in this approach in your mind identify what those 
are so that we can be sure to address those as the 
revisions are made. 
So let me just call on Board members.  Is there 
anyone who wishes to point out some what you think 
is a concept or area that needs to be added or 
significant changes?  I’m not looking for word­
smithing right now. 
MR. GRIFFON:  Paul, before we move on to that, can 
I just ask Lew or Larry a question about the Y-12 
petition? 
DR. ZIEMER:  Sure. 

MR. GRIFFON:  Is there a calendar issue here?  When 

did the clock start ticking, and when is the 

deadline for this evaluation report? Are we --

MR. ELLIOTT:  Well, the clock started ticking when 

the petition became qualified, and we met the 180 
day deadline and provided an evaluation report to 
the Board that spoke to the early years of Y-12.  
And we are still pursuing the remainder years for 
that one petition. 




























remaining years? I don’t understand it, but it’s 
not an issue any more or... 
MR. ELLIOTT:  Well, I don’t believe we see it as an 
issue, that we met the 180-day mark by providing a 
recommendation to the Board, an evaluation report 
on the early years, and we have provided a 
recommendation essentially to the Board that we’re 
continuing our evaluation on the remainder of that 
petition pending the resolution of the site profile 
issues. 
DR. ZIEMER:  We’ve also, those initial deadlines 
have been met. Now action is with the Board and 
there’s, the clock doesn’t really run for now.  Is 
that correct? 
MR. ELLIOTT:  I believe that’s the way we would see 
it.
Mark, does that answer your question? 
MR. GRIFFON:  Well, it’s an answer, yeah.  I just, 
I thought that the entire, that an SEC petition had 
to have an evaluation report for all members of a 
class by that given deadline.  I know this is a 
little different because it’s been sort of merged, 
it merges three different petitions, but I’m a 




























MR. ELLIOTT:  I think it’s a matter of how one 
interprets the amendment language, and I don’t 
believe the merger contributes to the issue here, 
the merger of three petitions.  It’s actually one 
petition that we haven’t provided a complete 
resolution for the petition.  We’ve provided a 
recommendation in the evaluation report that 
resolved the early years and recommended a class.   
And we stated therein that we were pursuing the 
evaluation for the latter years.  And now we feel 
that we need to hold on coming forward with any 
recommendation on those latter years until we have 
resolved the site profile questions. 
DR. ZIEMER:  Thank you. 
Let me return to my previous remark now Board 
members. On the work group product any comments or 




MR. GIBSON:  Paul, this is Mike. 

DR. ZIEMER:  Yeah, Mike. 

MR. GIBSON:  I just have a little bit of, I’d like 

to ask Jim maybe if he could comment for me.  The 

difference in feasibility and plausibility seems to 






























be a difference between feasible and plausible.  
Plausible to me means something that it’s just, 
it’s seemingly or apparently that you could or 
could not do something as opposed to feasible.   
I mean there seems to be a distinct difference, 
but yet these words seem to be used 
interchangeably, and I just wondered if Jim could 
comment on that or if they feel the same way, or 
they might consider changing that language a little 
bit. 
DR. MELIUS:  Yeah, Mike, this is Jim Melius.  As I 

indicated while I was presenting this, that is a 

little bit confusing and it has something to do 

with sort of the outline that we wrote this from.  

And we were using them somewhat interchangeably 

when we were talking in the work group meeting in 

Cincinnati. And I think they just need to be 

separated out a little bit.  And that may be the 

easiest way of doing it. 

DR. ZIEMER:  But perhaps some clarification of the 

use of those terms in the document.  Okay, thank 

you, Mike. That’s a good point. 

DR. DeHART:  Roy DeHart. 






























top here and say that we certainly agree from the 
NIOSH side that we need to be clear on what 
plausibility and feasibility mean.  But in a, after 
number one, plausibility and feasibility, at the 
end of that passage there it speaks about the upper 
bound estimates must be plausible.  I think that is 
appropriate use of that word in that context.  And 
when we were talking about feasibility, we were 
talking about the feasibility of doing dose 
reconstruction. And then when you start applying 
the different methods (inaudible) data you bring in 
plausibility. 
DR. ZIEMER:  Yeah, there is a distinct difference 
and we need to clarify that.  I think the point’s 
well made. 
Jim, we need to make sure that that’s clear in 
the document. 
MR. ELLIOTT:  I’m sorry, Roy. 
DR. DeHART:  Not a problem. It was simply a 
comment that addresses both issues. And that is in 
the discussion that was held, it became very clear 
that evidence based is one of the major decisions 
on what NIOSH is doing as it applies (inaudible) 



























that the fact that evidence based is so critical 

that in the information section where we’re trying 

to explain to the world what’s happening, there 

needs to be an incorporation of the phrase and an 

explanation of what is meant by evidence based. 

DR. ZIEMER:  Thank you, Roy.  Where would that be 

in the document? 

DR. DeHART:  I don’t think it’s in the document per 

se that you have, you’ve been reviewing.  It’s in 

the discussion that occurred in Cincinnati. 

DR. ZIEMER:  Oh, okay, but where would it be 

incorporated in the --





DR. ZIEMER:  Thank you. 

DR. MELIUS:  Yeah, this is Jim.  I agree with that.  

I was a little hesitant to use the term since it’s 

so widely used now in the medical world, but I 





DR. ZIEMER:  Thanks, other comments? 

DR. ROESSLER:  Yes, this is Gen. 






























DR. ROESSLER:  Under the section 
representativeness, for example, number four where 
it talks about sufficient data, i.e., is it 
statistically robust.  And then there’s another 
area where something with regard to statistics is 
mentioned. I think I’d like a little clarification 
as to what do we mean by, in that case, 
statistically robust?  How would that be identified 
or, you know, what would the test be? 
DR. ZIEMER:  Actually, and Jim, I guess this is 
considered you have to determine whether that’s 
something that has to be in the document or whether 
the burden is simply on NIOSH in each case to 
demonstrate that something is statistically robust.  
I don’t know whether a definition is called for 
here or not. Maybe that should be considered, but 
the point is made. 
And Jim, I assume you’re taking notes on these? 
DR. MELIUS:  I am. 
MR. GIBSON:  Dr. Ziemer? 
DR. ZIEMER:  Yes. 
MR. GIBSON:  This is Mike again.  Is this just an 
internal Board deliberation or is the public going 





























DR. ZIEMER:  Well, the document will certainly be 
made public. I’m not sure it’s on the website yet, 
but it’ll be part of our deliberations for the next 
meeting so it’s going to be a public document. 
MR. GIBSON:  I’m just saying at that point is the 
public going to have input on what determines the 
approach for an SEC petition as far as our 
criteria? 
DR. ZIEMER:  Well, I think let me answer that in 
part and maybe NIOSH can also.  I think on any 
petition the public has opportunity in the public 
comment period to comment on any issue in the 
petition. Members of the public could, for 
example, try to make the case for why something 
isn’t statistically robust for example or whatever 
issue they have with, relative to our procedures.  
So I think that, I believe that opportunity exists, 
and I’ll call on Larry if you want to comment 
further on that. 
MR. ELLIOTT:  Well, I think you’re absolutely 
right. It does exist at that point.  There’s 
opportunity for public comment also when the Board 
takes up this document for further deliberation at 
your next meeting.  There’ll be a public comment 




























DR. ZIEMER:  Mike may be asking for its application 
in particular, Mike you can speak for yourself, in 
particular cases will the public have an 
opportunity to, for example, indicate that they 
think that the procedure is not being followed in 
some way or was that the issue you were raising? 
MR. GIBSON:  Yeah, I’m discussing this house in 
particular. When we deliberate this, will the 
public have input? 
DR. ZIEMER:  Oh, yes. 
MR. GIBSON:  Okay, thank you. 
DR. WADE:  I think -- this is Lew Wade -- I think 
another strength to this document once it’s been 
vetted and exists, is that it could be read by 
people who were contemplating preparing a petition, 
and they could use this document to frame their 
argument given the fact that this is the Board’s 
sense of how it would be evaluated.  I think that’s 
providing really a great service. 
DR. ZIEMER:  Thank you. 
 Other comments or issues? 




























DR. ZIEMER:  Thank you, go ahead. 
MS. MUNN:  I have a little bit of a problem with 
this robust, too. I always have. I think it goes 
back to the nebulous nature of, or perhaps I should 
say the individually interpreted nature of what a 
term might mean. As I’m sure all of you are aware, 
prior to the last decade the term robust was 
usually applied to a person’s health.  And suddenly 
it became a very popular term in term, in the 
business and academic world.  And I’ve never been 
able personally to identify when something becomes 
robust and when it does not.  I think it may 
depend, like beauty, on the eye of the beholder. 
DR. ZIEMER:  I can’t define robust, but I know it 
when I see it. Is that right? 
MS. MUNN:  Yeah, that’s exactly -- 
DR. ZIEMER:  Well, I think perhaps in the document 
we might have, we might be able to discuss it in a 
little more definitive way, and then as I say in 
particular cases it may be up to NIOSH to show that 
statistically something is strong.  And obviously 
there’s a continuum. 
MS. MUNN:  It would be helpful I think, even Mr. 





























now, and he’s talking about things that exhibit 
strength or vigorous health and it’s... 
The one other thing, a completely overarching 
concept which may or may not be appropriate for 
this document, but it’s one that concerns us 
continually and comes up time and time again, is 
the issue of timeliness. We have concerns 
ourselves about, very strong concerns about the 
timeliness of what we do, and how we can do it.  
And certainly, every single one of the claimant 
population regardless of whether or not they’re in 
a special exposure cohort, are very concerned with 
the timeliness of our activities.  It is, when we 
issue documents like this, it would seem judicious 
for us to consider the possibility of phrasing our 
timeliness issues in such a way that we incorporate 
something about the limits of resources that are 
available to accomplish these things.  I know we’re 
trying to outline here how we feel things can be 
most expediently done, but realistically, if we do 
not help identify for the public that there are 
limits to the resources involved in producing these 
documents and doing dose reconstructions, then I 
don’t think anyone else is going to make that 




























we at least make reference when we talked about 

timeliness to the fact that all of the things we do 

are of necessity. 

DR. ZIEMER:  Certainly a good point.  You may want 

to provide some suggested wording that Jim might be 

able to incorporate into that part of the document, 

if you would please. 





DR. MELIUS:  Well, even if you don’t -- this is 





MS. MUNN:  Thank you. 

DR. ROESSLER: Paul, this is Gen. 

DR. ZIEMER:  Yes, Gen. 

DR. ROESSLER:  In offering our critique, I didn’t 

mean to overlook the fact that I wanted to comment 

on the overall document.  I think this group has 

done an excellent job.  And I agree with Wade that, 

or Lew Wade, that I think by doing this, this helps 

everybody and it helps possible petitioners and so 

on. And in particular I think they’ve done a good 

job of identifying the four key principles.  Thanks 































DR. ZIEMER:  Other comments? 

MR. GIBSON:  Paul, this is Mike again. 

DR. ZIEMER:  Yes, Mike. 

MR. GIBSON:  I think what Wanda was pointing out, I 

think may have just kind of alluded better to what 

I was saying about feasibility and plausibility.  

There is a limit on technical information and time 

and money and et cetera.  And is it feasible to do 

an accurate dose reconstruction as opposed to using 

the word plausible?  I think that further -– 

DR. ZIEMER:  Right, I think you’re right, Mike, and 

that in some cases has to do with resources 

available and even some of the other parameters 





 Other comments? 
 (no response) 
DR. ZIEMER:  If not, this does not require action 
today, but we will look for a revised copy to come 
before the Board hopefully at our next face-to-face 
meeting later this month.  Again, thank you, Jim, 



























document. Another comment? 

MR. GIBSON:  Yeah, this is Mike again. 

DR. ZIEMER:  Yeah, Mike. 

MR. GIBSON:  So if I understood NIOSH correctly, 

just let me clarify this, we’re going to deliberate 

this draft at the next meeting, and there will be 

room for the public comment -- 

DR. ZIEMER:  Yes, that’s correct. 





DR. WADE:  Correct. 

MR. GIBSON:  Okay, thank you. 

DR. MELIUS:  This is Jim Melius.  I will try to get 

a copy to Lew after I get comments in from people 

and the comments have been raised so far, get a 

copy over to Lew, say ten days or a week or so 

before the next meeting so they can post the draft 





DR. ZIEMER:  And perhaps at least to address Mike’s 

concern about public input, we need to make sure 

that we schedule this on the agenda for a time 






























period so that those, we might alert the public to 

it. It’ll be available, and if people wish to 

comment on it, they could.  Or we could have our 





DR. WADE:  Right, I think what we’ll do is we’ll 

schedule two public comment periods.  At the first 

we’ll make sure that everyone is aware of this and 

the fact that it will be discussed. And then we 

can hear comment from them as we might like, then 

we would have a discussion of the issue. 

DR. ZIEMER:  So we’ll try to make sure that happens 

that way, Mike. 

MR. GIBSON:  Okay, thank you. 

DR. ZIEMER:  And you make sure it does, too. 

DR. WADE:  Let me be clear. I wasn’t clear on my 

words. There are two public comment periods.  The 

first public comment period will alert people to 

this. Then we’ll have a second public comment 

period where they can come, and then after that 

second public comment period we’ll deliberate.  So 

I think that meets your intention, Mike. 

MR. GIBSON:  Right, thank you. 































Mark raised because I don’t want to gloss over it.  
And that is that the 180 days and the issuance of 
an evaluation report that, it’s our interpretation, 
the interpretation at least how that speaks to me 
that that requirement only applies once to the 
issuance of the initial evaluation report. 
Once that requirement has been met, there could 
be long discussions with the Board as there was in 
Mallinckrodt. There could be iterations in the 
issuance of further evaluation reports.  There is 
no clock running there, only the initial clock for 
the issuance of the initial evaluation report. 
So Mark, that’s in part an explanation to 
what’s going on here. Certainly NIOSH, if it was 
going to modify that report substantially, would 
have to do that before the Board was to take up the 
discussion of the SEC petition at a Board meeting. 
MR. GRIFFON:  I mean, I guess I, you know, I just 
am, I was a little surprised, Lew, because I know 
there’s been a lot of push.  Even at the last Board 
meeting you seemed to suggest that we really needed 
to move with the working group and move so that 
NIOSH could complete an evaluation report to 
present at the next Board meeting.  I just had that 





























mind. And I’m just a little concerned that now is 
a completely open-ended.  I’m sure that all of us 
will be trying to close it out ASAP, but I guess 
that I just wanted a little more clarification on 
how this opinion was arrived at. 
DR. WADE:  I think there’s always a timeliness 
pressure on the Board regardless of the 180 days.  
And I think it would have been ideal if we could 
have voted on the Y-12 later years SEC at the end 
of January. But what I hear from NIOSH is they are 
not in a position to issue an evaluation report 
substantially at this point; and therefore, I think 
the only prudent thing to do is to wait. 
MR. ELLIOTT:  I don’t know if it’s of any 
consolation, but I have spoken with the petitioners 
and explained the current status and the decision 
that we have made regarding evaluating the 
remainder of their petition.  They were certainly 
thrilled, of course, that we added a class for the 
early years, and they seemed very understanding and 
accepting of our need to resolve the issues around 
the site profile before we move forward with the 
remainder of their petition. 
DR. WADE:  But the alternative we face, Mark -- and 




























been to force NIOSH to issue an addendum to their 

evaluation report that would have been incomplete 

and likely changing. And we would have been down a 

Mallinckrodt path, and I don’t think we want to do 

that again either. 

MR. GRIFFON:  Well, yeah, I understand the 

technical constraints certainly, but -- 

DR. WADE:  This is the conundrum I mentioned 

earlier. We’re going to have to deal with this in 

many shapes and sizes as we move forward because of 

the Board’s desire to be complete in its 

deliberations with the site profile before it takes 

up an SEC, and the fact that there are time 

pressures associated with an SEC. So this is 

something we’re going to have to get better at. 

MR. GIBSON:  Paul, this is Mike. 

DR. ZIEMER:  Yes, Mike. 

MR. GIBSON:  Does anyone have the exact language on 

the law for the SEC’s because it seems like I 

remember it -- I’m kind of like Mark.  It seems 

like something to the effect that all the 

documentation must be ready within 180 days or 

something like that, not just parts and pieces or, 





























MR. ELLIOTT:  We don’t have it here in front of us 
but the language reads, “a recommendation”. 
DR. WADE:  We will read the language either, right 
after lunch we’ll get the language, and we’ll read 
it. 
DR. ZIEMER:  We can return to this -- can you have 
it now? 
Hold on just a minute here, we’re trying to get 
MR. ELLIOTT:  The language that specifies -- 
DR. ZIEMER:  Well, let’s, we’ll get the language 
and see what, and clarify it here in a little bit, 
Mike and Mark, and make sure.  I think NIOSH 
believes that they have met the requirements -- 
MS. HOMOKI-TITUS:  Dr. Ziemer? 
DR. ZIEMER:  Yes. 
MS. HOMOKI-TITUS:  I’m sorry. This is Liz Homoki-
Titus. I just joined the call. I have the 
language. “Deadlines, not later than 180 days 
after the date on which the President received the 
petition for designation as members of the special 
exposure cohort, the Director of NIOSH shall submit 


























Health a recommendation on that petition including 

all supporting documentation.” 

DR. ZIEMER:  We have received a recommendation. 

MR. GIBSON:  But, this is Mike again. 

DR. ZIEMER:  Yeah, Mike. 

MR. GIBSON:  Including all supporting documentation 

would be provided within 180 days? 

MR. ELLIOTT:  On the recommendation. 

MS. HOMOKI-TITUS:  Right, it’s all supporting 

documentation on the recommendation. 

DR. ZIEMER:  I believe Larry had told us that the 

one part of the recommendation was that additional 





MR. ELLIOTT:  Yes, in the evaluation report we said 

specifically that we would continue the evaluation 

for the latter years.  

DR. ZIEMER:  That was the recommendation. 





DR. ZIEMER:  Yeah, Bob. 
































similar action, and we roll it, or you all decide 
to roll it into the SEC, does the clock start all 
over again or is it still a 180-day clock? 
MR. ELLIOTT:  The clock starts all over again on 
that petition when it becomes qualified. 
MR. PRESLEY:  Okay, all righty. 
MR. ELLIOTT:  But if it is qualified, the 180-day 
clock for that petition starts. 
MR. PRESLEY:  That’s what I thought.  Thank you. 
DR. ZIEMER:  Any further comments on that? 
 (no response) 
REPORT FROM WORKING GROUP ON
Y-12 SITE PROFILE
MR. MARK GRIFFON, GROUP CHAIR
DR. ZIEMER:  I think we can move ahead on our next 
agenda item, which is a report from the working 
group on the Y-12 site profile.  You should have 
Mark’s report which is a draft report.  I believe 
he sent it out over the weekend, maybe the seventh.  
Mark’s group, the working group just met last 
Thursday so he had to scramble to get this report 
out. 
But anyway, there’s a working group report, 
which is -- I’m looking for page numbers to see how 



























Mark’s report that was e-mailed out over the 
weekend? It’s called “Summary of Work Group 
Meeting Discussion and Action Items”. 
MS. HOMOKI-TITUS:  Dr. Ziemer? 

DR. ZIEMER:  Yes. 

MS. HOMOKI-TITUS:  I didn’t get it. I don’t know 

if LaShawn didn’t get it or didn’t have the 

opportunity to send it out to us. So if somebody 

has it by e-mail, that would be great, otherwise 

I’ll just look at a copy of it later. 

DR. ZIEMER:  Can somebody e-mail it to Liz right 

quick? Or can we get it out to Liz? 

MR. GRIFFON:  The same with the matrix. 

MS. HOMOKI-TITUS:  I didn’t get any of these 

documents so Emily can just fax them to me at 

lunch. That’s fine. 





MR. GRIFFON:  Are we going to start these after 





DR. ZIEMER:  Well, let me ask what the Board would 




























you want to --





DR. ZIEMER:  No, the matrix was sent out in, I have 

the matrix as dated at November 12th . 

DR. NETON:  That November 5th matrix will -- I don’t 

want to speak for Mark, but a matrix will be coming 

out of the product of the working group, I think. 

DR. ZIEMER:  An updated matrix. 

DR. NETON:  An updated matrix which will be a 

summarized version of -- 





MR. GRIFFON:  Yeah, I sent an updated matrix -- 





MR. GRIFFON:  Did I not distribute the updated 

matrix? It should be a shorter matrix. 



































MR. GRIFFON:  Not really. I have a five-page 
matrix which sort of puts in matrix form what’s in 
the summary notes so it’s really just maybe an 
easier way to look at it.  But I can also try to e-
mail that at lunch. I, myself, I would like to 
take a lunch since I’ve scheduled a phone call for 
that time. 
MS. MUNN:  I don’t think the shorter matrix may 
have gotten --
DR. ZIEMER:  I didn’t get a shorter matrix and 
NIOSH doesn’t appear to have it here either, Mark.  
Would you e-mail that out? 
MR. GRIFFON:  Yes, I will. I think I e-mailed it 
to Joe Fitzgerald for his quick review from SC&A’s 
standpoint. 
MS. MUNN:  Yeah, I think that may have been the 
case because --
MR. GRIFFON:  I probably didn’t distribute it to 
everyone. I’m sorry. 
MS. MUNN:  Yeah, I still have that monster with 135 
items on it. 
MR. GRIFFON:  I’ll e-mail that right now, and then 



























DR. NETON:  Mark, who are you going to send it to?  

Will you send it to me, maybe? 









MR. GRIFFON:  -- and then the entire Board I’ll 

send it to. 

DR. NETON:  I can print out my copy here and -- 

DR. ZIEMER:  Liz, do you need a copy? 

MS. HOMOKI-TITUS:  I would like to get one, but I’m 





MR. GRIFFON:  And Lew, you’re on my mailing list.  

Can you forward it to others that need it? 

DR. WADE:  Yes, I will. 

DR. ZIEMER:  Okay, then we’ll take a recess for, 

till one o’clock.  And just for housekeeping, does 























you’ll call back in in one hour, one o’clock 
eastern time, 12 o’clock central and so on, early 
morning out there in Hanford. 
MS. MUNN:  And waking up time for Wanda. 
DR. ZIEMER:  You can go get breakfast now, Wanda, 
and then come back.  Okay, we’re recessed till one 
o’clock. 
(Whereupon, a lunch break was taken at 11:52 a.m., 





























AFTERNOON SESSION 1:00 P.M.
DR. ZIEMER:  I think we can go ahead and get 
underway. During the lunch hour we had a request 
that the motion that was approved this morning on 
Bethlehem Steel be reread into the record, and Lew, 
do you have that -- yes, I have it here. Let me read 
that motion again.  It’s the motion that was approved 
by Board vote this morning relative to Bethlehem 
Steel. Here it is. 
“It is the opinion of the Board and the Board’s 
contractor that, based on the information available at 
this time, the Bethlehem Steel site profile as modified 
through the comment resolution process is acceptable for 
use in the NIOSH Dose Reconstruction Program with the 
understanding that the action items listed in the 
attached matrix will be completed and that NIOSH will 
track all ongoing action items and provide the Board with 
quarterly updates on each of the six items listed in the 
matrix.” 
And that is the action that was taken this morning. 
DR. WADE:  Thank you, Paul. 
This is Lew Wade. I -- again, evolving our technique in 
terms of holding these kinds of conference calls so if at 
any point there’s someone on the call who feels compelled 





























please don’t be shy. Whether we’re, we’ll be able to do 
that or not, I don’t know. But don’t be shy in terms of 
making a request. We really want not only transparency 
but enlightened transparency so people can understand 
what we’re talking about. 
DR. ZIEMER:  In some cases such as the matrix, we can 
make it available by e-mail. 
Hang on, we’ve got an extraneous phone going off. The 
Chairman forgot to turn his phone off. I think that was 
a call to order exactly what it was. 
MS. MUNN:  The Chairman is to be complimented on his 
choice of musical --
DR. ZIEMER:  Yeah, in place of a gavel we have to use 
that. 
I already took a roll call. The only one that was 
missing from this morning is Anderson. Did Dr. Anderson 
come online yet? 
 (no response) 
DR. ZIEMER:  Still not back. Well, we’ll proceed. 
DR. WADE:  We have a quorum and --
DR. ZIEMER:  We have a quorum and perhaps he’ll be 
joining us shortly. 
The item that’s before us now is the report from the 
working group on the Y-12 site profile. We have two 





























had distributed over the weekend, and now we’ve added to 
that the five-page matrix to support that document. 
So Mark, with that, do you want to --
DR. WADE:  Might I -- just before Mark begins, this is on 
the altar of conflict of interest. We’re going to be 
talking about the Y-12 site profile. There are three 
members of the Board who are currently identified as 
conflicted on Y-12: Dr. Ziemer, Mr. Presley, Dr. DeHart. 
Again, our procedures on a site profile are that those 
individuals can be involved fully in the discussion. 
They can stay at the table. They can contribute as they 
would. If there was to be a vote, they would recuse 
themselves. We don’t anticipate a vote on this issue, 
but just again to be transparent, that’s the situation. 
MR. PRESLEY:  Understood. 
DR. ZIEMER:  Thank you. 
Okay, Mark, let me turn the mike over to you, and you can 
proceed. 
MR. GRIFFON:  I just wanted to make sure that there’s a 
narrative and the matrix, and the other thing I should 
say right up front is that the both of those refer back 
to a December 19th report put together by SC&A, I believe, 
and edited by NIOSH, which was the conference call notes 
from the December 19th, 2005 meeting. 





























in this draft you’ll see like Issue 1-A and Items 1, 2 
and 3. Items 1, 2 and 3 are laid out explicitly in the 
previous set of notes. So you might have to do a little 
bit of cross-walking to completely follow these 
documents. 
And then one other bit of information for this is that, 
and we tried to highlight this in the summary notes, that 
these items, while this is a site profile review, the 
focus clearly has been on the issues which the work group 
and which SC&A actually identified them out of their 
overall findings. 
And they basically looked at the overall findings 
and said, of these, which ones are likely to affect or 
may affect the SEC petition before us. So we clearly 
focused on sort of these major items that could likely 
affect, and it doesn’t necessarily reflect all the 
findings in the original Y-12 review that SC&A did. As 
an additional homework assignment this weekend, I did 
take these and sort of cross-walk back to the original 
findings. 
And it’s not always that straightforward. There was 
a very lengthy matrix that NIOSH put together, and if you 
look back at SC&A’s original report, there’s eight basic 
findings but under each one of those findings there’s 





























want to be clear that this is not necessarily the 
universe of findings in the original SC&A report, but 
rather the work group’s evolved to these sort of findings 
that we believe are the major items of interest or of 
concern with regard to the SEC petition before us. 
And then just walking through them, the format, there’s 
internal dose is divided up or is up front, and each, 
under each issue there might be some items listed within 
a certain issue. And then for each, there’s sort of a 
discussion of each, of what went on at the work group 
session. And then below that there’s the actions 
related, or actions that came out of the discussions. 
And we felt like, I mean, it’s actually good that we did 
this quickly from the Thursday meeting because we want to 
make sure we stay on top of these actions as we move 
forward. As you can see -- well, let’s walk through the 
pages. 
Issue 1-A, validity of data, items 1, 2, and 3, I 
rolled those together because in our discussion of this 
topic, items 1, 2 and 3 sort of overlap a bit and we sort 
of discussed all three at one time. Basically, there has 
been progress from the last meeting. NIOSH has made some 
data, some data available on the website, on the server 
actually, on the O drive so that SC&A and the Board have 





























urinalysis records from ’50 to ’57 and external 
monitoring records. But there remains to be quite a bit 
of work done in terms of validity of, and verification of 
that data. 
Is somebody going to ask a question or... 
DR. ANDERSON:  This is Andy. I just came on. 
DR. ZIEMER:  Okay, thanks, Andy. 
Go ahead, Mark. 
MR. GRIFFON:  Let’s see. 
MS. MUNN:  Reliability. 
MR. GRIFFON:  Yes, and Wanda, I hear Wanda’s comment. We 
did have a discussion during this, and it’s captured in 
the discussion topic here, of as we were talking about 
validity, validation of the data, there were some 
concerns about that term being used for this process and 
people interpreting it differently. It has a certain 
relevance in the research arena, and, you know, we’re in 
a compensation program. 
So I think we’re trying to clarify through the work 
group process what exactly we, we’re, you know, what 
exactly they need to do to prove or to demonstrate, I 
guess, that this is reliable is the new term that we 
threw around at the work group sessions, that the data’s 
reliable to use for dose reconstructions. 





























discussion sort of ended up was that more needs to be, 
there is going to, I think that NIOSH raised some 
concerns about the fact that it’s going to be likely very 
difficult to uncover raw records, raw laboratory logbooks 
or data cards, et cetera, associated with this data. So, 
you know, how can they demonstrate the reliability of the 
data? 
And we’ve discussed other possible means such as 
cross-walking with health and safety reports such as 
looking for quality control reports, past quality control 
reports from the time period, other items like that which 
are, some of which are outlined in the action items. So 
I don’t think, I think we’re still asking NIOSH to pursue 
whether there exists raw data, but I think they might 
report back to us, you know, how easily or not so easily 
accessible that data is. So I think that’s the crux. 
The other --
DR. ZIEMER:  Mark, can I interrupt --
MR. GRIFFON:  Sure. 
DR. ZIEMER:  -- just for clarification? And in this case 
by reliability, you’re asking how well the secondary set 
of information represents the original dataset? 
MR. GRIFFON:  Yes. 
DR. ZIEMER:  Okay. And this has nothing to do with how 





























of what is actually in the record. What you have is on a 
disk did you say? 
MR. GRIFFON:  Yes. So we have a database, electronic 
database. 
DR. ZIEMER:  Electronic database. 
MR. GRIFFON:  And also the other part of --
DR. ZIEMER:  But that was generated by who? By DOE? 
MR. GRIFFON:  Well, this was by, yes, apparently this was 
Y-12 data transferred directly to the Center for 
Epidemiological Research, CER, because I use that acronym 
in here. 
DR. ZIEMER:  Not associated necessarily with this program 
but sometime in the past? 
MR. GRIFFON:  Right. My understanding, Jim, Jim Neton, 
correct me if I’m wrong on that. 
DR. NETON:  Right, this is an exact, we believe, a copy 
of the database that Y-12 uses for their radiation 
protection program. 
DR. ZIEMER:  So if there were some way to even sample 
selected pieces of this against an original, that would 
be a validation procedure, but that’s the issue then. 
MR. GRIFFON:  That’s the issue, right. 
DR. NETON:  We believe that these records may be in the 
Atlanta Records Center or some place like that which 





























arose as to what, when you have hundreds of thousands of 
records, what’s a representative, you’re going to say 
it’s verification or validation, then you get into the 
scientific issue --
DR. ZIEMER:  Yeah, well, you need a robust sample is what 
you need. 
DR. NETON:  We did spend some time debating what that 
really meant. 
DR. ZIEMER:  Okay, thanks. 
 Mark, proceed. 
MR. GRIFFON:  Jim, I could hardly hear you on that last 
comment, but --
DR. NETON:  I think Paul’s paper may be covering up the ­
-
MR. GRIFFON:  Anyway, the other part of the database is 
the, one other factor in there was in the urinalysis 
database I believe there is this question of a lot of the 
values say calculated values, and they’re dpm for 24-hour 
period I believe. And a question was raised as to how, 
you know, how these were calculated. 
And we received some information on that from an 
annual report of 1965. We asked for some more follow up 
on that, just how were raw data values converted to dpm 
per 24-hour period as entered in the database? So that’s 





























but they’re a little different. 
And I think that covers, I mean, I’m not going to 
read through every action item, Paul, unless --
DR. ZIEMER:  No, actually these action items are fairly 
recent, right? 
MR. GRIFFON:  Yes. 
DR. ZIEMER:  So these are things that NIOSH will be 
working on --
MR. GRIFFON:  Yes, and I --
DR. ZIEMER:  Lew, for clarification, are these things 
NIOSH has already agreed to? 
MR. GRIFFON:  As of an e-mail this morning, I think, Jim. 
DR. NETON:  By eight o’clock, I got the e-mail over the 
weekend, but I wasn’t aware that --
DR. ZIEMER:  Well, I wasn’t clear whether you’d agreed to 
this in the working group and Mark is just recording it 
or --
DR. NETON:  No, actually as of about, that’s right, about 
eight o’clock this morning I reviewed this document, and 
we have nothing of substance to add or --
DR. ZIEMER:  Okay. 
MR. GRIFFON:  I would also note to all, you know, SC&A 
and NIOSH and work group members, I think these are still 
draft and I can still make edits to these after this 





























DR. ZIEMER:  Yeah, and keep in mind this is just a status 
report here. We’re not taking action on this today. 
You’re just giving the Board a status report. 
MR. GRIFFON:  Right. 
DR. ZIEMER:  -- giving the Board a status report. 
MR. GRIFFON:  And I should note, if you look in the 
matrix, I don’t know if it came across in the summary 
notes as well, but in the matrix these pretty much 
tracked one to one, they should anyway. But in my third 
column I say outstanding action items, and the reason I 
put it that way is because the last conference call notes 
that you have, December 19th, there are other actions in 
here which, you know, I want to give NIOSH credit on 
progress they have made. 
And I started to go back to the original findings 
and make the matrix, but it was just becoming too 
confusing over the weekend for me to pull all that 
together because the number schemes are different and 
everything. But they have, all these actions that we 
have now are outstanding ones, but that doesn’t mean that 
in between December 19th and last week’s meeting there 
wasn’t any progress. 
There was some progress. We have access to some 
databases and things like that, and they have responded 





























I just want to make that point that these are now new 
action items. They might have been carried over, but 
they’re essentially the outstanding action items. 
MS. MUNN:  Mark, this is Wanda. I made very few notes 
during our meeting. I was relying on other people to be 
my memory for me. But I did have three comments down 
here, and one of them is clearly covered in the 
compressed, the matrix that we have here. 
But a couple of them I’m not sure whether they were 
covered. And actually the first one I am not certain 
whose action it was and precisely what we were talking 
about. But I made a note, “will track through manuals to 
find out where the conversion numbers came from.” Was 
that covered in this last item you were just discussing? 
MR. GRIFFON:  Yeah, the conversion factor. That should 
be item 4, item number four, yeah. 
MS. MUNN:  Right, just wanted to make sure that was 
covered. And item 1, back on the third page, 1-c-1 under 
Action Item 2, when you were talking about NIOSH was 
sending a copy of the spreadsheet, I had noted “action 
NIOSH get to SC&A the key for collapsing the data into 
these larger categories.” Was that captured? 
MR. GRIFFON:  I think that is the spreadsheet. 
DR. NETON:  Yeah, there were two spreadsheets, Wanda, and 





























MR. GRIFFON:  It might be spreadsheets, yeah. 
MS. MUNN:  Okay, I had thought somehow that there was 
another step in there somewhere that was necessary to 
make that conversion clear, but if this spreadsheet does 
it, great. 
MR. GRIFFON:  Yeah, I think it does it, yeah. And as Jim 
mentioned, this is real time. And I saw Jim Neton’s e-
mail come across that said that they’ve updated one of 
the external, I think the external monitoring database. 
They’ve added job titles now, and that’s what the action, 
so they’ve already partially completed some, you know, 
they’re working on these. It’s real time. 
MS. MUNN:  Yeah, my sense is they’re moving quickly on 
this. 
DR. ZIEMER:  Okay, Mark, proceed. 
MR. GRIFFON:  All right, I guess we can then go to page 
three which is item 4. We’re under -- this is not my 
numbering system by the way. Issue I-a, item 4 is what 
we’re kind of looking at, and intake of insoluble uranium 
and there is an action item. There’s one action item for 
this, which is basically to, that NIOSH agreed to further 
look. I think this is a carryover action to further look 
at this question of high-fired uranium oxide. And I 






























DR. NETON:  Yes, we discussed this and I think we stated 
our position, but we need to follow up with the 
references that SC&A provided us to verify that what we 
think is the case --
MR. GRIFFON:  Right. 
DR. NETON:  -- fleshed out a little bit. SC&A has 
posited that there may be super Class F uranium at Y-12 
and these two references that are listed here are offered 
in support of that position. And we need to look at that 
and see if they really do (inaudible) to it or whether it 
speaks really more to the type F. 
MR. GRIFFON:  But we did have a discussion on the effect 
on the dose reconstruction, and I think for the most 
part, I mean, correct me if I’m wrong, Jim, but for 
cancers of interest here, lung cancers primarily, you 
would assume Class S, and they would likely be 
compensated under the current model anyway. Is that --
DR. NETON:  That’s right, anyone who had any, anyone who 
was on a monitoring program, for example, missed dose 
alone for lung under solubility Type S which would be 
over the 50th percent mark or PC. Then you’re left with 
systemic organs, and if you assume that the materials 
were very insoluble in the lung, that would tend to 
reduce the doses to the systemic organs. So we believe 






























It doesn’t, in our opinion, it does not have a real 
practical significance on dose reconstruction outcomes 
for the --
MR. GRIFFON:  It may be less of a issue in terms of this 
SEC evaluation than was originally thought, but that 
action’s still on the table for this one. 
DR. NETON:  We did agree that it is a generic issue 
related to, it particularly affects a large number of 
uranium (inaudible) to address it in some way. 
MS. MUNN:  It would be a good thing to put to bed. 
MR. GRIFFON:  Moving on unless there’s any other 
comments, Item 5, In Vivo Results and Coworker Models, 
and the real question that was raised was why there 
weren’t in vivo results used in any way in the coworker 
models. And I guess the primary point for our discussion 
here is in the oldest part of my text. That, you know, 
that there’s no data prior to 1960, and therefore the 
issue does not really affect the ’50 to ’57 petition at 
hand. 
And then from the other respect, I guess, the, 
generally speaking, we had a discussion on the detection 
limits of the in vivo versus urinalysis and the fact that 
in most cases the in vivo will be used to sort of, maybe 





























really used in terms of calculating the actual intake. 
Is that correct, Jim? 
DR. NETON:  That’s correct. 
DR. ZIEMER:  But there’s no action item --
MR. GRIFFON:  No actions under that because of the 
highlighted section. That’s why the action, it doesn’t 
mean that it’s not still an entry --
Section 1-b then moves into the question of other 
radionuclides, and the primary discussion here at Y-12, 
well, there’s several twists and turns to this discussion 
actually. But the question of how the site profile 
addresses exposures to other radionuclides other than 
uranium and these include, but not, but I’m not going to 
state that they’re limited to, polonium, plutonium, 
thorium, gallium, the transuranics from the recycled 
uranium. I think that’s some of the primary ones. And I 
think -- oh, Uranium-233 also and possibly this radium 
improgeny (phonetically) associated with radium and 
radon, et cetera. 
And then, I guess, this, you know, we had some 
discussions about several things here. One is just, 
apparently one of the big things that came out of this 
meeting was that they have recovered a, ORAU, I guess, 
has recovered or identified a CD or a set of data that’s 





























images, and it’s a little unclear how much data that 
actually is. 
There might be some repetitious pages in there I 
guess, but it does have some thorium, some of this data: 
plutonium, thorium. I’m not exactly sure what isotopes 
of interest might be on there, but it seems to be stuff 
that might be related to the cyclotron, calutron 
operations. Is that accurate, Jim? Maybe you can 
describe that better. 
DR. NETON:  Yeah, I guess that’s the best we can say 
because neither of us has seen it. It’s hard to say. 
MR. GRIFFON:  Right, so which leads us to one of the 
action items which is that they need to follow up on 
this, Action Item 2 actually, “Follow up on additional 
data currently under classification review.” And that’s 
something for us also to keep in mind is that this CD 
rests down there at Y-12 under classification review. 
And it’s unclear, at least to me from our meeting, how 
long that might take to be declassified, or if it can be 
all declassified. So it’s just something to keep in 
mind. 
MR. GIBSON:  Jim, Mark? This is Mike. 
DR. ZIEMER:  Who’s speaking? 
MR. GIBSON:  Mike. 





























MR. GIBSON:  If this new data involving the plut (sic) 
and the thorium if it cannot be declassified, obviously 
it would require Q-clearance. How’s this going to affect 
the impact on the SEC evaluation? 
MR. GRIFFON:  I’ll defer that question. 
DR. ZIEMER:  I don’t know if Jim or Larry can answer 
that. And also while they’re thinking about that, in 
declassification, does anyone know if things can be sort 
of partially declassified? For example, can we learn the 
identity of nuclides even though they may not be able to 
tell us quantities? 
DR. NETON:  Yes, I think that’s true. 
DR. ZIEMER:  So we can get at least partial information. 
DR. NETON:  Right, and maybe, like I say, it might not be 
possible to get the job and the department codes for the 
different bioassay results, that sort of thing, job 
titles. 
MR. GRIFFON:  I think that’s going to be the biggest, 
knowing a little bit about Y-12, I think the biggest 
concern is going to be linking those isotopes to certain 
areas, the buildings or --
MR. GIBSON:  Doesn’t it -- this is Mike. 
MR. ELLIOTT:  I think you’ve already said enough on that, 
but yes, the way we would proceed on this would be that 





























ORAU’s Q cleared folks. We’d understand at that point 
what is being held still as classified information after 
the classifiers review. 
We would make some decisions on whether or not we’d 
be able to move forward in our SEC evaluation report or 
would we need to call the Board’s attention to what was 
being held back. And perhaps you would have your 
contractor or your classified or your cleared Board 
members peruse this as we did for Iowa. 
MR. GIBSON:  Yeah, I guess the question I’m getting back 
to is how do the petitioners, how are they going to have 
basically due process? They’re trying to get information 
to prove their point on their SEC petition, if they, you 
know, they obviously don’t have a Q clearance. 
MR. ELLIOTT:  That certainly would be taken into 
consideration as to whatever is being held back, and we’d 
have to see what information is being retained as 
classified and make a determination as to whether it 
prohibits us from making a clear evaluation publicly 
about the petition or not. 
MR. GRIFFON:  Yeah, I guess we’ve got to take this a step 
at a time. 
DR. NETON:  I think it’s a little premature to judge 
because what Mark hasn’t talked about yet is the CER or 





























the extent that that is a subset maybe or part of the 
6,000, you know, pages. We don’t know. 
MR. GRIFFON:  Right. 
MR. ELLIOTT:  But just to be clear on Mike’s question, we 
have to (inaudible) counsel’s advice and led to 
understand that there’s no requirement on presenting an 
evaluation report that all information that supports that 
evaluation report has to be out in the open. We would 
like it to be. We want it to be. We want to be as 
transparent as possible. And then too, if it were to be 
a finding and determination that we would, say, deny the 
class, and by the way, there’s information that is of a 
classified nature that we can’t speak about that enables 
us to provide this recommendation and say that we can do 
dose reconstructions, I think that’s the worst case 
scenario that we’d have to think about, and think about 
how we could do that in as transparent as possible format 
without divulging national security information. 
MR. GIBSON:  This is Mike again. I just want to get it 
on the table. I know it may be, may or may not be an 
issue in the future, but it’s still something that I 
think we need to keep that a consideration so we won’t 
possibly have a train wreck down the road. 
DR. WADE:  Certainly, certainly, Mike, you’re correct. 





























everyone. I believe that we’re owed an explanation of 
that policy that came up at a, several meetings ago, and 
the Board had requested further information and also a 
briefing on that, and had suggested a discussion of how 
we would implement that. And to date we’ve received 
absolutely nothing. 
DR. ZIEMER:  You’ll get a follow up on that. 
DR. MELIUS:  If it’s basically going to become an issue 
with this particular site, it’s all the more reason that 
we need to move ahead and have some discussion of this. 
DR. ZIEMER:  So noted, thanks. 
Mark, you want to proceed? 
MR. GRIFFON:  Sure. 
MR. GIBSON:  Mark, one more thing. This is Mike. Is 
there, the advice from counsel that you mentioned, will 
that be made available to the Board? 
MR. ELLIOTT:  It has been made available to the Board. I 
believe Liz Homoki spoke to this on the record at 
previous meetings. There’s nothing in the act and 
nothing in our rules that prevent us from using 
classified information to do dose reconstructions. 
DR. MELIUS:  Again, Jim Melius, a reminder, I don’t 
believe we’ve ever received the decision. All we’ve had 
is your transmittal of that information to us through you 





























asked for and have never received a copy of that --
MS. HOMOKI-TITUS:  That’s because there was no written 
decision. 
DR. MELIUS:  Well, then we, all the more reason we need 
more explanation and more time for discussion of this. 
DR. ZIEMER:  Okay, thank you, so noted. 
Mark, you want to proceed? 
MR. GRIFFON:  Sure, we all done with that? 
DR. WADE:  We’re not all done with it, but --
MR. GRIFFON:  We’re not all done with it obviously. 
DR. ZIEMER:  But the issue’s been noted. 
MR. GRIFFON:  Yeah. 
And Jim is right in pointing out the fourth action 
item on that was that there’s an X-10 Department 4,000 
data and Department 4,000 is basically departments that 
were X-10 operations that were housed in Y-12 facilities, 
so it was X-10 work being done at the Y-12 facility. 
And anybody, I guess the understanding is anybody 
that was doing that kind of work was assigned to the 
Department 4,000 series in the department number codes. 
And they’re going to look at this data as well to see 
what kind of information is available there regarding 
these other radionuclide exposures. 
And I think that’s, one, I guess the fifth item also 





























issue, and I think that currently the internal dose 
section of the site profile uses a, basically a, the same 
ratios used throughout for the transuranic (inaudible) or 
(inaudible) exposure to the transuranics. 
And there was some questions about whether the 
material in any of the operations at Y-12 could the 
transuranic materials concentrate in any form whereby 
causing for greater ratios in some operations than in 
other areas. And the feeling from NIOSH and ORAU, I 
believe, is that it wasn’t likely that there were any 
operations, but they were going to follow up on that. 
DR. NETON:  Mark, I thought also that SC&A was going to 
review the relevant section of the internal dosimetry 
document. 
DR. ZIEMER:  Yes, this --
MR. GRIFFON:  I think you’re right, yeah. 
DR. ZIEMER:  -- is going to review --
MR. GRIFFON:  That’s right, I did say SC&A, okay. 
DR. NETON:  (Inaudible) had a version that had the 
recycled uranium addressed. And we agreed at the working 
group meeting that they would go back and look at it and 
comment. 
MR. GRIFFON:  That’s correct, it was a later version, 
that’s right. I’m sorry. 





























DR. MAURO:  Yes, I am, and I agree with that. 

DR. ZIEMER:  I’m not sure it’s your understanding, too, 

that, have you guys been made aware of this? 

DR. MAURO:  We are very much aware of it. 

DR. ZIEMER:  Thank you. 

Okay. 
MR. GRIFFON:  Thanks for that correction, sorry. 
Then Issue 1-c, let’s see, this is the, I think this 
relates to the -- I’m having trouble cross-walking myself 
so I can only imagine others. Oh, this relates to the 
choice of the 50th percentile intake rates, and there’s 
some discussion on how, when workers didn’t have 
monitoring, what distribution would be assigned. Would 
it be the entire distribution, the mean of the 
distribution, the 95th percentile? 
And I think it varies depending on information about 
the individual claimant. You know, what type of job, 
what areas, et cetera. And I think that SC&A was just 
looking for clarification on how that coworker model was 
going to be used to assign individual doses. And some 
action items out of that are listed one through four 
there mostly which I believe is to clarify the department 
and the job function, the job titles and job functions 
listed in the databases that we received. 





























comment came up during the discussion as to whether the 
sampling involved the, the database covered the monitored 
people likely to be most exposed. And I think there was 
some discussion as to whether it was the most exposed 
individuals or more likely it seems like it might have 
been the most exposed departments were sampled from. 
There’s a comment that random sampling was sort of 
done at departments of highest exposure potential. Bob 
Presley actually as a site expert I think may have a 
comment for us, and I think we just need to, I think that 
needs to be better understood, in my opinion anyway. I 
think that was one of our actions. 
I think that’s it. Any comments on those action --
DR. ZIEMER:  I have one question. Is it, do we know at 
this point how the monitored people were selected? Were 
they selected at random from the highest exposed groups 
as opposed to identifying the highest exposed 
individuals? Is that what you’re saying? 
MR. GRIFFON:  Yeah, that’s what we, I think that’s what 
we need to follow up on. 
DR. ZIEMER:  Because a priori they wouldn’t know who the 
highest exposed individual was going to be; and 
therefore, took the randomly assigned monitoring? 
DR. NETON:  That’s action item number three under 1-c. 






























DR. ZIEMER:  -- how that was done. 
DR. NETON:  We thought we understood it pretty well, but 
Bob Presley provided more information that indicated that 
it might not have been quite on the mark. So we just 
need to go back and see exactly what that --
DR. ZIEMER:  Go ahead. 
MR. GRIFFON:  Items 1-d/e, I think they kind of got 
merged together, in the last report. And this involves 
the, I think it’s the Type F uranium. Let me find it. 
Yeah, Type F uranium exposures and the 48 hour delay in 
sampling. And really the, I guess the two questions that 
are outstanding is just if, there is apparently a policy 
for a 48-hour delay in sampling after the exposure, sort 
of the Monday morning policy, although it might have not 
been a Monday morning all the time depending on what 
shift people worked. If this 48-hour delay was in 
practice, SC&A pointed out that the results could be 
underestimating when you use, the coworker models could 
be underestimating the intakes by a factor of, what, two 
to four? Is that --
DR. NETON:  Yeah, I think we decided a maximum of three 
at this point. 
MR. GRIFFON:  Okay, maximum of three, yeah. So I think 





























SC&A and Dave Allen from NIOSH are walking through this 
issue to try to determine whether in fact that this is 
the predominant pattern in the database, whether there 
was usually 48-hour delays in the sampling. And if that 
was the case, they’re going to agree upon a method for 
correcting the data that way. 
Is that accurate, Jim? 
DR. NETON:  Yeah, I think so. I think I’d like to say 
also if we can generally agree that this is not 
necessarily an SEC showstopper, it really would result in 
a, some sort of correction factor being applied to the 
bioassay coworker model. But it is important to get this 
issue ironed out and do an accurate dose reconstruction. 
MR. GRIFFON:  And the other thing, I guess, is the 
question of Type F uranium exposures and whether there 
were, I think in the current -- I might be wrong on this, 
but there’s just a question of whether Type F assumptions 
are used in doing dose reconstructions for any, any 
organs or if the worst case, non-metabolic always use 
Type M. 
DR. NETON:  Mark, I think what happens here, and we 
didn’t talk about this last week, or is it this week? 
Last week, was that if the 48-hour sampling issue can be 
shown not to be a problem, in other words, if they did, 





























other sampling periods we could use, then the Type F 
issue goes away because then I think what happens is Type 
M and F become the bounding dose reconstructions. 
MR. GRIFFON:  Yeah, I did, yeah. 
DR. NETON:  Under the, if they exactly followed 48-hour 
delays then Type F becomes a player. If we can show that 
that’s not really the case then the Type F issue kind of 
goes away, but we’re not there yet. 
MR. GRIFFON:  Right, but we’re not there yet so that 
action, I left that for that reason. Because one sort of 
depends on the other; they’re intertwined. 
And Issue 1-f is the job descriptions of unmonitored 
workers lacking is what the original issue is described 
as. And mainly I believe this focused on the unmonitored 
workers that SC&A had interviewed that didn’t appear to 
be, to fall into other job categories or departments. 
And therefore, it was a question of how they were going 
to be assigned from the coworker model I guess. I might 
have this wrong. SC&A or NIOSH can clarify that issue. 
DR. MAURO:  This is John Mauro. I’ll take a shot at it. 
When, my understanding was when we run into those 
circumstances where you’re not quite sure whether the 
person is unmonitored and you’re having difficulty 
judging what his responsibilities might have been, you 





























for that particular internal emitter. So there is a 
fallback position to deal with when you’re confronted 
with these types of uncertainties with regard to the job 
responsibilities.
And I’d kick this over to Jim or to Joe if he’s on 
the line and see if I correctly characterized that. 
DR. NETON:  Yeah, I think you got it, John. This is Jim. 
I think there’s one additional issue here and that was 
the exposure to the roving workers to the non-routine 
isotopes like plutonium and such. How would you handle 
that? And I think we discussed that if we did have 
access to a sufficiently, I use the term robust, database 
for plutonium and polonium and thorium, this issue would 
tend to go away. 
And as John characterized then it becomes the 
decision do we use the 50th percentile or the 95th 
percentile on those distributions for the, what we would 
call, the roving worker? So this is some way tied in 
with the answers to the other action items. 
MR. GRIFFON:  Well, that’s why, and if you look at my 
matrix, I tied it back to C actions and 1-b items one and 
two and 1-c-1. I think they are overlapped in the 95th 
percentile. You know, the how is the coworker dose 






























DR. NETON:  I agree. 
MR. GRIFFON:  But there’s no actions actually listed 
under 1-f that are covered by the (inaudible). 
DR. NETON:  For a second there I thought we had it all 
put to bed, but --
MR. GIBSON:  Mike. I have a question here. We had, I 
think, talked something about on these roving workers 
that, you know, they may have been employed by Y-12 or to 
X-10 or vice versa and stuff. And we’d talked about 
trying to resolve whether or not they were going to be 
included in the Y-12 site profile or SEC or the X-10 site 
profile or if there would be an SEC. Did that, did I 
miss that or did that get resolved? 
MR. GRIFFON:  I think Jim -- that’s a good question 
actually. I mean I think currently the way we’ve been 
discussing is that for employees working in those Y-12 
operations, we’re covering them under this SEC petition 
evaluation. Is that --
DR. NETON:  That’s correct. At one point NIOSH raised 
the issue of ownership -- and I use that term loosely --
that the calutrons and cyclotrons at Y-12 were 
transferred from Y-12 to X-10 in 1951, the question 
became under what facility should those dose 
reconstructions or those SEC petitions be evaluated. And 





























activities occurred on the Y-12 site, we’re going to 
address them as a Y-12 issue. 
MR. GRIFFON:  Right. 
DR. ZIEMER:  Where are you working at? Who’s paying the 
bill? 
DR. NETON:  Right, because there’s issue. Ownership is 
sort of a loose term when you talk about the fact it’s 
all owned by the Department of Energy. It’s really more, 
in my estimation, a bookkeeping function more than 
anything. 
MR. PRESLEY:  This is Bob Presley. That is one hundred 
percent correct. 
MR. GIBSON:  This is Mike. If I’m hearing you right, it 
doesn’t, it’s not a matter of who they were employed by 
as far as a contractor; it’s where they were. 
MR. PRESLEY:  This is Bob Presley. That’s correct. We 
were all Union Carbide employees, and you either worked 
at one of the three sites. 
DR. ZIEMER:  Okay, okay, Mike? 
MR. GIBSON:  Yes, so it doesn’t really matter who managed 
the operation. It was where they worked. 
DR. NETON:  If the work was performed on the Y-12, within 
the confines of the Y-12 fence line, I guess is the way 
I’d put it, we’re going to consider that as a Y-12 





























MR. ELLIOTT:  (Inaudible) based, the petition (inaudible) 
DR. ZIEMER:  And can I ask a related question? This is 
Ziemer. Do they show up in the Department of Labor 
records when the Department of Labor is determining 
eligibility? Do they show up as a Y-12 person even 
though they may have been an X-10 employee? Or is that 
an issue that is handled separately. I mean, we may be 
calling them that. I want to make sure Labor does when 
they --
DR. NETON:  That’s a good question. I --
DR. ZIEMER:  -- because Labor has to establish their 
eligibility for the class, does it not? 
 (no response) 
DR. ZIEMER:  And if they show up as being an X-10 
employee is Labor going to say, well, they weren’t? 
MR. ELLIOTT:  They will have to verify the eligibility 
for each member of the class based upon the time they 
worked at that facility. 
DR. ZIEMER:  At that facility. 
MR. ELLIOTT:  They’re going to have to develop that 
aspect of a person’s claim. If you were employed at X­
10, but you say here you, in the interview with NIOSH 
that you worked at Y-12 on the calutron operation x 
number of days or months, they need to establish that. 





























right, Paul, good point there. 
DR. ZIEMER:  Go ahead, Mark. 
MR. GRIFFON:  External dose I think we’re up to. Yes, 
Issue 1, Data Validity and Coworker Models. Items 1, 2 
and 3 actually are very similar to what we discussed 
under internal dose which is the question of the validity 
or maybe now the reliability. I haven’t changed words 
because the titles were there before, but we did, as I 
said, we did discuss the difference. 
And this again is looking at the Y-12 external data 
which is also CER data which I also understand was 
directly taken from the Y-12, a direct copy of the Y-12 
database. So this question originally Item 3 in the 
December 19th report was questioning whether the CER or 
HERB electronic data files included all the Y-12 workers 
or a subset. And by subset there, we’re talking about 
like a subset for research purposes, like all white males 
before a certain time period or something like that. And 
it’s pretty clear it’s not. It’s just a direct copy of 
the Y-12 database. That’s our understanding now. 
Okay, and the action items listed, as I said, Jim 
has already responded I think to one of these. We asked 
for a larger query on the overall database to go up to 
1965. ‘Fifty to ’57 covers the petition at hand, but 





























extrapolate earlier exposures. So to evaluate this, we 
really need the later data as well. That’s one action 
item. 
We also asked for the, the second one’s very similar 
actually in my mind. That might be a duplicate. The 
third is a specific subset related to the coworker model. 
The 147 monitored workers had to be in a separate file 
for review. 
And then Item 4 goes back to this. We asked NIOSH 
to at least assess whether and how difficult it would be 
to compare the database against hard copy records, data 
cards, et cetera, to check the reliability of the data. 
And then Item 5 is very similar also to the internal 
dose section where we ask for, that they provide or 
review quality control reports or procedures from the 
early years as a reliability check. So I think that’s it 
for the --
DR. ZIEMER:  Okay, go ahead, Mark. Something broke in 
there. 
MR. GRIFFON:  All right, Item 4 under this was going back 
to the original. On the December 19th report it says, 
“NIOSH to rationalize how a 90 percent match between the 
electronic record and the Y-12 monitoring records are 
sufficient for dose reconstruction purposes in contrast 





























ORAU report 22. And I think that still is an outstanding 
item that hasn’t, we didn’t get a report back from that 
so that was just a kind of a carryover action item. 
Is that correct, Jim? 
DR. NETON:  That’s correct. 
MR. GRIFFON:  And Item 6, I don’t even know if we 
discussed it, but there was a carryover action item I 
guess. Let’s see, oh, the coworker models, I think it 
actually came up in the earlier discussion and they, 
NIOSH did agree that they would make available the 
analytical files. These are Excel spreadsheets. I think 
at least one of them is a crystal ball analysis-type 
model for the coworker models versus any external dose. 
And to my knowledge, I don’t think SC&A had reviewed 
these. 
Is that correct, John? 
DR. MAURO:  That’s correct. One of the decisions we came 
to at the meeting was the protocol where you use the 1961 
through ’65 data to go back to pre-’61 involved a set of 
data and also a set of statistical procedures in order to 
reconstruct the pre-’61 data. And during the meeting we 
agreed that SC&A would look at that protocol and those 
data. 
DR. ZIEMER:  So there’s an SC&A action item. 





























at the meeting we did agree that we would have our 
statistician take a look at that protocol. There was at 
one time, you may recall, we did review that procedure, 
and there was some discussion back and forth where there 
was some general agreement. Yes, this procedure is 
valid; we had certain questions regarding it. I don’t 
believe those issues yet have been engaged. So it’s a 
matter of having our statisticians talk to your 
statisticians along with the dataset that that 
statistical tool will be operating on. 
DR. NETON:  That’s one good point you raised, John. I 
think we did agree at the working group meeting that it 
was appropriate for us to set up small technical 
discussions among our various parties to iron out these 
details and then report back with a, you know, transcript 
or a summary of the work that transpired. 
DR. MAURO:  Yeah, I think that that item is missing from 
the –- that we’re looking at it. I think that item is 
missing from the matrix, probably should --
DR. NETON:  I think in some ways that’s sort of been our 
standard operating --
DR. ZIEMER:  Right, it’s kind of built in here, but in 
some cases we may want to identify the specific SC&A 
actions. This is directed toward the NIOSH actions, but 





























we may want to make a note of it as well. 
Thanks. 
Okay, Mark. Still there? Mark? Hello. Anybody? 
 (no response) 
MS. MUNN:  I don’t know that Mark is still there. 

MR. PRESLEY:  This is Bob Presley. I’m still here. 

DR. ZIEMER:  We’re still on the phone call. We thought 

we lost everybody. 

DR. ANDERSON:  Andy’s still here, too. 

DR. ZIEMER:  Okay. 

MS. MUNN:  I have a question of John with respect to the 

SC&A item we were just identifying as being an action 

item. Where do you see that going on this compressed 

matrix that we --

MR. GRIFFON:  Hi, I just got cut off. I’m sorry. 

DR. ZIEMER:  We were just asking where the SC&A action 

would be in the matrix. Is it 1-a-6? 

DR. MAURO:  It’s 1-a-6 in my mind, yes. 

MS. MUNN:  Okay. 

DR. ZIEMER:  That’s where I put it. 

Okay, Mark, we’re ready. 
MR. GRIFFON:  What was that SC&A action? 
DR. ZIEMER:  One-a-6, we just talked, John Mauro had 






























MR. GRIFFON:  Oh, going to review the spreadsheet? 
DR. ZIEMER:  And we’re going to add that in our matrix to 
make sure we track it even though the focus is on the 
NIOSH actions. 
MR. GRIFFON:  Right, right. 
DR. ZIEMER:  But there is an SC&A action involved there 
as well. 
MR. GRIFFON:  Sure. I don’t know what happened. I got 
cut off there. 
MS. MUNN:  We missed you. 
DR. ZIEMER:  I think we’re ready for 2-a, Mark. 
MR. GRIFFON:  All right, Issue 2-a, Badging of Maximally 
Exposed -- I think again this is a question of a coworker 
model and how it’s going to be applied I think. Is that 
accurate? 
DR. ZIEMER:  It overlaps to what we talked about before. 
MR. GRIFFON:  Right, except for the internal versus 
external. 
DR. NETON:  It’s just the external dosimetry version of 
the internal --
MR. GRIFFON:  Yeah, right. 
MS. MUNN:  Yeah. 
MR. GRIFFON:  And I don’t know if in this case --
DR. NETON:  There was this criticality issue that Kathy 





























written this up yet, but we determined that that area was 
actually clean before they went in there, and the uranium 
leaked by a valve that was supposed to be shut. 
DR. ZIEMER:  Are you talking about the June ’58 
criticality? 
DR. NETON:  Right. 
DR. ZIEMER:  Well, you know, there was an extensive 
mockup to assign dosimetry to those workers. 
DR. NETON:  We have a dosimetry, and we’ve actually 
reconstructed some doses for those cases. But the issue 
raised by SC&A was that how could we argue that people 
were, the highest exposed individuals were badged when 
people that were working in the area where a criticality 
occurred did not have badges? 
And the answer, I think, is that that area was not 
supposed to be contaminated, that the tanks that they 
were working on had already been cleaned at one point. 
And unbeknownst to the workers the valve had been open 
that leaked enriched uranium into the tank. And then 
when they poured it in the drum, it became critical. 
So it doesn’t defend whether those workers should 
have been monitored or not, but it does not negate the 
policy we think was in place which was that people who 
were the highest exposed workers were thought to be the 





























we need to write up and demonstrate. 
DR. ZIEMER:  They probably had blood sodium from them as 
well. 
DR. NETON:  I think everyone that got a security badge 
had (unintelligible) --
DR. ZIEMER:  Yes. 
DR. NETON:  Which is, I think, how they triaged those 
workers. But I think Kathy agreed that it wasn’t the 
fact that a criticality occurred. It was that they were 
working with uranium-bearing materials, and they weren’t 
badged. And it’s up to NIOSH to demonstrate that we 
don’t believe at that time there was sufficient external 
exposure in that area to have been badged under their 
typical operating procedure. 
MR. GRIFFON:  That’s actually not why I paused, but 
that’s such a good point, Jim. The reason I paused was I 
was wondering whether a similar question that Bob raised 
on the internal monitoring, I don’t know if it is or is 
not applicable here. You know, was there a question as 
to whether there is, I think you, I don’t know if it’s 
been determined whether the maximally exposed, all 
maximally exposed individuals were monitored or there 
were, you know, you certainly have heard of cases where 
the monitor, certain individuals from work groups have 





























know if that --
DR. NETON:  If you remember, Mark, ORAU’s done a lot more 
work in this area, and we’re much more comfortable saying 
that we believe the workers who should have been badged, 
who had the highest exposures, were, and we don’t believe 
that it was cohort badging at all. In the internal area 
I think we need to do a little bit more work. 
MR. GRIFFON:  That’s what I thought. That’s the only 
reason I paused when I saw that badging of maximally 
exposed, and I wasn’t sure if that had been cleared up or 
not cleared up or --
DR. NETON:  Well, in my mind it is, but then again, I 
can’t (unintelligible). 
MS. MUNN:  This is another one of those instances in 
which the issue that Mike raised earlier comes up, 
whether it was plausible or whether it was feasible. It 
was probably feasible to have everybody monitored, but it 
wasn’t plausible to expect that these people would be 
exposed. There ought to be with any luck at all enough 
evidence from the post-accident scenario and information 
to be able to make that decision clear I would think. 
MR. GRIFFON:  Oh, yeah, I’m not necessarily talking about 
that action anymore, but I was talking in general in the 
database. 





























MR. GRIFFON:  Anyhow, I think we’ll leave that, I mean, I 
think we can leave that with those two actions unless 
there’s any input on that. 
DR. ZIEMER:  Mark, does that complete this? 
MR. GRIFFON:  No, there’s a couple more in there. 
DR. ZIEMER:  I’m sorry. We have 2-b. 
MR. GRIFFON:  Two-b is Coworker Dose Assessment. The 
main discussion that we had here was about TIB-51 which I 
think is related to neutron exposures and whether the NTA 
film needs to be corrected or can monitor for neutron 
exposures of the lower neutron energy levels. And also, 
I guess, the characterization question. And I think this 
has been just recently provided to SC&A. So SC&A is 
going to review TIB-51, provide comments to NIOSH, and 
then have a discussion of that. And that can be prior to 
a work group meeting or a Board meeting, in between, 
whatever. 
And the second issue is more or less a carryover 
issue which is on the skin extremity dose reconstruction 
procedures which I don’t think were really addressed in 
the original site profile. 
Is that correct, Jim? 
DR. NETON:  That’s correct. 
MR. GRIFFON:  So those are under development, and I also 






























And finally, the last thing there, I just wanted to 
capture the fact, and it didn’t really, these notes are 
organized in the order that they were from the December 
19th meeting. These example cases were actually presented 
in the middle of the internal and external discussions in 
this meeting. But I just tore out the back of these 
notes. 
We did, Dave Allen primarily, although I don’t know 
if other NIOSH staff members were involved in the 
development of these cases, but Dave Allen presented 11 
cases. And these were adjudicated cases. 
Is that correct, Jim? 
DR. NETON:  I believe so. 
MR. GRIFFON:  Or are these completed DR cases? And they 
were for the most -- well, let’s see, six lung cancers. 
We didn’t go through every one of the lung cancers 
obviously. Dave did one or two of those to demonstrate 
sort of how the coworker model was used at least in a few 
of them. And I think the upshot of a lot of this was 
that I think we, as the work group moves ahead, and as we 
get more information back from NIOSH, I think we need to 
outline parameters for other cases that we’d like to see 
dose reconstructions performed on. 





























of proof of principle. How they’re going to go about a 
dose reconstruction for, you know, a person who worked in 
the calutron or, you know. I’m not sure what the 
parameters are yet, but these cases that we looked at 
looked fairly straightforward, and we may want to choose 
other cases that better demonstrate that they can do it 
for all members of the, they can complete dose 
reconstructions for all members of the class within the 
petition. 
DR. NETON:  Mark, this is Jim. I think the intent of 
those cases was that we would demonstrate the application 
of the coworker data for uranium workers only. 
MR. GRIFFON:  Right. 
DR. NETON:  And we tried to throw in the recycled uranium 
component and demonstrate the plausibility of doing these 
dose reconstructions with either the full distribution or 
the 95th percentile. And I think the numbers look fairly 
reasonable, but I agree. There’s a lot of other examples 
that would be necessary to flesh out all the other subtle 
exposure types that may have occurred here. 
MR. GRIFFON:  And at this point, I mean, it wasn’t 
criticism necessarily. Just where we are right now I 
think that we can’t really select other types of cases 
until we know a little more about these other 





























MS. MUNN:  I think it’s also worthwhile to note -- this 

is Wanda -- that nine of those 11 cases were compensable. 

MR. GRIFFON:  Right. 

DR. ZIEMER:  Okay, Mark, thank you. 

Let me ask if there’s any further questions or 
comment on the report? 
 (no response) 
DR. ZIEMER:  We’ll then be expecting an update on this at 
our face to face meeting in a couple of weeks, and Lew 
wants to address this relative to the petition. 
Lew. 
DR. WADE:  Let me just walk through this issue in some 
detail so that we’re all on the same page. And I 
apologize if I add confusion to an already confusing 
issue. It’s certainly not my purpose. 
About a month ago it would have been my hope that 
following the working group meetings that Mark chaired 
and then following this Board meeting, we would have 
reached resolution on the pertinent issues of the Y-12 
site profile that impacted the Y-12 SEC petition. This 
is for the years ’50 to ’57. 
After this meeting I was assuming that NIOSH would 
issue an addendum to its evaluation report, and then we 
would go to the meeting in Oak Ridge. And the Board 





























confess now that that was a naïve belief on my part. 
What we’ve now learned is that there is still more work 
to do to reach intellectual closure on the site profile 
as it impacts the SEC petition. 
So what I see happening now is that between now and 
the meeting at the end of January, NIOSH and SC&A will be 
working hard to advance according to this resolution 
matrix. At the meeting at the end of January in Oak 
Ridge, the Board will have a robust discussion of the 
technical issues related to the site profile. The Board 
will then have a robust discussion of Dr. Melius’ thought 
piece, “Report of the Working Group on Special Exposure 
Cohort Petition Review”, we’ll hear from the public on 
that. 
And then with these two discussions behind us, the 
Board will then discuss how it would like to proceed from 
a time point of view towards the issue of closing on the 
site profile and the SEC petition. And you’ll be seeing 
a modified “Federal Register” notice for the meeting at 
the end of January that will reflect the things that I’ve 
just talked about. 
I am sorry for the confusion that was brought about 
over this issue, but I do think it’s terribly important 
that we try and reach closure on the issues related to 

































addended evaluation report by NIOSH. So that’s where we 
stand now. I see nothing but the highest quality work go 
into this. Sometimes that work takes time though. 
DR. ZIEMER:  Thanks, Lew, and thanks to Mark and Wanda 
and Mike and Robert for all their work on this Y-12 site 
profile, and we will then take this up again at the next 
meeting. 
DR. WADE:  And one final word to the new Board members, 
it looks like the Y-12 SEC petition will really happen on 
your watch. So I’m glad that you’re here hearing these 
discussions. 
UPDATE ON SCIENCE ISSUE: LYMPHOMA DOSE
RECONSTRUCTION TARGET ORGAN SELECTION
DR. JIM NETON
DR. ZIEMER:  We have another item now on our agenda, and 
that is an update on science issues and more specifically 
the issue of the lymphoma dose reconstruction target 
organ selection. And Board members, you should have 
received now -- well, we had a presentation actually in a 
meeting last year on this issue. 
And then you should have received recently from 
Larry the proposed change in the IREP program. Help me 
if I -- it is a proposed change in the IREP program. No, 
it’s not a change in the program. It doesn’t change the 
program per se. It does affect the outcome of the IREP 
calculations. 





























think outside, independent evaluations that were provided 
by Dr. Crowther and Keith Eckerman. And make sure you 
have those, and then there’s the, just a summary -- I 
think this came from you, Larry -- called “Summary of 
NIOSH’s Re-examination of Lymphoma Target Organ 
Selection”. So those are the pieces of documentation 
that you should have. And Larry, he’s going to lead the 
discussion. I know Russ is here today, Russ Henshaw. 
DR. NETON:  The record should show that we have Brandt 
Ulsh and Russ Henshaw joining us for this discussion, and 
they’re from NIOSH. 
DR. ZIEMER:  And Brandt’s going to lead us or Russ. 
DR. NETON:  I will --
DR. ZIEMER:  Jim will kick it off and the others will 
support. 
DR. NETON:  I think there’s not much more to add here 
other than to refresh Board members’ recollections of 
what we proposed at the Board meeting in Knoxville. 
And that was that we had come to conclusions looking 
at the scientific evidence related to lymphomas that our 
target organ selection for non-Hodgkins lymphoma in 
particular was not scientifically correct. We went to 
some lengths to get expert opinions from a Board-
certified hematologist as well as a expert health 





























The end result of that analysis revealed to us that 
for internal dose in particular, we were previously using 
what we would call the highest non-metabolic organ, that 
is, we would calculate the dose to all the organs and 
select the organ that had the highest dose among the ones 
that weren’t explicitly modeled for our metabolic model 
and assign that for lymphomas. 
We are proposing at this point to use, particularly 
for internal exposures, the tracheal-bronchial lymph 
nodes, thoracic lymph nodes, for reconstructing internal 
dose. This would in effect raise the internal doses to a 
large number of previously processed cases, with non-
Hodgkins lymphoma cases. 
And we propose to go back and re-evaluate those 500. 
In addition to that there are 500 cases being held 
pending until the decision is made so that we can finish 
and complete those dose reconstructions. In our mind the 
internal dose reconstruction is the big change here. I 
mean, we’re talking in the order of magnitude of more 
change in the internal dose for those organs, those 
lymphomas. 
The external part of the organ is changed slightly 
but is not significantly. We’re proposing to you the 
lung as a surrogate for dose to the lymphocytes for 





























change. These are percentage-type changes as opposed to 
the order of magnitude changes that occurred in the major 
target organs for internal dose. 
If I haven’t confused anybody, I guess I can answer 
questions on that. 
DR. ZIEMER:  This is a proposal that requires Board 
action. It is not mandatory that the action be taken 
here today, but if the Board is comfortable taking action 
today, we can certainly do that. 
Let me open the floor for discussion. Basically, 
this comes as a recommendation from staff asking for the 
Board to approve this change in the methodology. 
Board members, any questions or comments? 
MS. MUNN:  This is Wanda. It appears to me that as 
thorough a job of garnering expert counsel as possible 
has been done, and the draft dated 1/6/06 that’s going to 
the “Congressional Record” appears to be very 
straightforward and comprehensive in my view. I’m 
willing to accept this as a reasonable and accurate 
motion, action for NIOSH to take. 
DR. ZIEMER:  Thank you. 
Other comments, pro or con? 
DR. DeHART:  This is Roy. Returning back to when we had 
the presentation, I think there were a number of us that 





























is done that we were assuming something that was entirely 
inappropriate for circulating lymphocyte cancers and so 
on that the biopsy site would be the site identified. 
And I think this makes total sense to return to what is 
physiological. 
DR. ZIEMER:  Okay, thank you, Roy. 
DR. ROESSLER:  This is Gen. I have a question. 
DR. ZIEMER:  Gen, go ahead. 
DR. ROESSLER:  A lot of this decision is based on the 
work of Dr. Mark Crowther. And I’ve looked at his 
credentials, and they look very good. But my question is 
when someone is selected to make an evaluation like this, 
who is involved in the decision making? And at this 
point does everyone pretty much agree that he is the 
expert in this area? 
DR. ZIEMER:  Who can answer that for --
MR. ELLIOTT:  Well, I’ll take a stab at this, Gen, and 
ask Jim and Brandt to fill in the cracks that I might 
leave. 
Certainly, when there is a scientific element in 
dose reconstruction that’s being called to question, the 
staff bring that forward to Jim Neton’s attention and to 
my attention. We ask them who are the external experts 
that we could seek out for consultation on an issue. So 





























Once we have a pool of viable experts assembled, we 
approach individuals in that pool and seek out their 
willingness to provide this type of consultation as you 
see from Dr. Eckerman and Dr. Crowther. It is not an 
exhaustive search for expertise, so I want to make that 
clear. And it is narrow in its –- it’s shallow in the 
pool as far as the folks that are known or recognized by 
internal staff or other people that we talk to about the 
issue. 
DR. ZIEMER:  Gen, does that answer your question? 
DR. ROESSLER:  Yes, I think so. I know the other expert, 
Keith Eckerman, is certainly as recognized by health 
physicists, and in my view everybody would agree that he 
is the expert there. I just wanted a little more 
discussion on the other to make sure there was total 
agreement. 
DR. ZIEMER:  Okay. 
MR. ELLIOTT:  I would also offer this, that we are 
publishing in the “Federal Register” a notice that we’re 
proposing this change. You see that in this 1/6/06 draft 
for the “Federal Register”. We hope that that will be 
presented in the “Federal Register” tomorrow. I’m 
awaiting a call to confirm its publication, but we 
believe it will be there tomorrow. 





























open for 15 days, and we would hope and welcome that the 
Board could make a, come to a decision on this today and 
then 15 days hence, the publication of the “Federal 
Register” notice, we would be prepared to consider any 
public comment and move forward in accordance. 
DR. ZIEMER:  Thank you. 
Okay, other comments or questions? 
DR. MELIUS:  This is Jim Melius. I just am sort of 
trying to understand what we’re approving. What we’re 
really approving, if I understand it correctly, is the 
document called “Summary of NIOSH’s Re-examination 
Lymphoma Target Organ Selection” dated October 31st, 2005? 
That is the detail, I mean --
DR. NETON:  What we’re asking for advice from the Board 
is the technical information bulletin that was issued is, 
in effect, is that is the change in our approach for 
target organ selection scientifically reasonable? 
MR. ELLIOTT:  And so we’re asking the Board for 
consensus, comment or recommendation regarding that 
proposed change. And we’ve tried to spell out the 
proposed change and show you how it would look in our 
technical information bulletin on this topic as well as 
provide the Board with a summary statement of the issue 
along with outside expert consultation remarks, Jim 





























Board back in October. I think that’s the extent of all 
the documentation we’ve provided. 
DR. ZIEMER:  I think, Jim, the official document is OCAS 
TIB-012. 
DR. NETON:  That would be revision one. 
DR. ZIEMER:  Rev. 1. 
DR. NETON:  It would help you garner what’s changing in 
there though. We’ve provided you a summary of what the 
relevant changes would be and a rationale for such 
changes. So they’re sort of two companion pieces, but 
ultimately the change would be reflected in this TIB-012 
as to how would we go about doing dose reconstructions 
and re-doing them as well. 
DR. ZIEMER:  Procedurally, I’m going to ask the question, 
maybe I’ll address it to Lew, if the Board makes a 
recommendation, and this will be published in the 
“Federal Register”, and you’ll get comments, and you’ll 
have to take those into consideration as well, the Board 
would be another piece of that? 
MR. ELLIOTT:  Yes. 
DR. ZIEMER:  Does the Board’s recommendation in this case 
need to go to the Secretary or is it simply a piece of 
input basically to the program? 
MR. ELLIOTT:  Your recommendation can come to the 





























The (inaudible) calls for public comments to be sent to 

my attention. But you advise the Secretary so I think 

you’d want to --

DR. ZIEMER:  We can at least inform him. 

DR. WADE:  Yes, you can do both. 

DR. ZIEMER:  Okay, Board members, you have the materials; 





MS. MUNN:  This is Wanda. I’ll be glad to make the 

motion that the Board accept the proposed changes to OCAS 

TIB-012 as shown in rev. 1 and as condensed in the 

information being presented in the “Federal Register” 

during this coming week. 

DR. ZIEMER:  Okay, you’ve heard the motion. I think the 

initial wording was the Board accepts or –-

DR. WADE:  The Board accepts the recommendation. 

MS. MUNN:  Accepts the recommendation. 

DR. ZIEMER:  I’m not sure it’s a recommendation to the 

Board per se. It may be that we support the proposal, 

Wanda, if that’s agreeable. 

MS. MUNN:  Accept the proposed changes to OCAS --

DR. ZIEMER:  Is there a second to that motion? 

MR. PRESLEY:  Bob Presley, I’ll second it. 


































MR. GIBSON:  This is Mike. I have a couple of questions. 
DR. ZIEMER:  Sure. 
MR. GIBSON:  NIOSH has said that if we adopt this they’re 
willing to go back and re-look at the claims that have 
been denied if I understand them right, correct? 
DR. ZIEMER:  That’s correct. 
MR. ELLIOTT:  That’s correct, Mike. 
MR. GIBSON:  Does DOE, does DOL also put on record as 
stating that they would re-adjudicate these claims or re-
look at these claims also? 
MR. ELLIOTT:  So they’re aware of this proposed change 
and through the various program evaluation reviews that 
we do here. That’s a term that we use, program 
evaluation review. When we make a change in how we do 
dose reconstruction or in our site profile, a technical 
information bulletin, there is an effort to go back and 
look at all cases that have been done under the previous 
version of that document, whatever document it may have 
been, and examine whether or not that change would have 
resulted in the claim being compensable. So we always 
look at those claims that are not, that have been done 
and were found not to be compensable. 






























MR. ELLIOTT:  Yes, they have an obligation. 
DR. NETON:  This is provided for in our regulation for 
dose reconstruction that if we identify a case where we 
believe that the new information would change 
compensability, we notify both the claimant and the 
Department of Labor of that. 
DR. ZIEMER:  Yeah, Mike does that answer the question? 
MR. GIBSON:  I guess what I’m saying is if a claim was, 
maybe NIOSH recommended the claim be compensated and 
DOE/DOL denied this claim, and you go back and re-do this 
claim again, is DOE/DOL prepared to look at the claim 
again with an open mind? 
MR. ELLIOTT:  Well, I think there’s a little confusion in 
your statement, Mike. The claims that we have done thus 
far would be re-examined by us. And if we identify a 
dose reconstruction we’ve already done, and it was a non­
compensable dose reconstruction, and this change made it 
cross the 50 percent line and become compensable, we 
would notify the claimant and we’d notify DOL. And DOL 
would pick up the revised dose reconstruction we’d 
provide to them and produce a probability of causation 
greater than 50 percent and pay the individual. 
DR. ZIEMER:  And they would be obligated to do that? 
MR. ELLIOTT:  Yes. 





























 (no response) 
DR. MELIUS:  This is Jim Melius. I have a sort of a 
procedural question. I mean, you have a very small 
amount of information on the medical condition of the 
claimants. Isn’t most of that information handled by the 
Department of Labor? 
MR. ELLIOTT:  Yes, it is. They’re the responsible party 
for determining eligibility of the claim, and that’s one 
of the eligibility points of determination that the 
person has cancer. And they base that determination on 
the, you know, some very sparse information such as a 
physician’s report of diagnosis to a death certificate. 
DR. MELIUS:  Right, and I’m just saying that implementing 
this policy I think is going to be difficult without, I 
don’t know if we’re going to have adequate information 
for categorizing people here. 
DR. ZIEMER:  I think that’s probably the case in some 
cases. 
MR. ELLIOTT:  I think that’s the purpose of the change 
that we’re proposing. It’s going to make it easier. 
DR. NETON:  It’s going to make it easier, and Brandt 
should speak to that. 
DR. ULSH:  Yeah, Jim, in cases where we don’t have the 
ICD code down to the fifth digit, and that’s probably a 





























OTIB, I’m sorry, this revised OCAS TIB, procedures for 
handling that. And that is we default to the most 
claimant-favorable choice. 
DR. NETON:  But also for non-Hodgkins lymphoma the fact 
of diagnosis no longer is relevant. They will 
automatically default for internal exposures to the lymph 
nodes of the thoracic lymph nodes. Prior to this we have 
been requiring the Department of Labor to provide us as 
definitively as possible the site of diagnosis of a non-
Hodgkins lymphoma which we now believe to be not relevant 
to the etiology of the illness. 
DR. MELIUS:  Correct, okay. 
DR. ZIEMER:  Because it should be an improvement if any. 
MR. ELLIOTT:  This aids us in doing our work, and your 
point is well taken, Dr. Melius, that in many of these 
diagnoses of cancers do not come forward with a clinical 
pathology that would allow us to reconstruct right down 
to the cellular level, but this is an attempt to get 
around that and to be more, to acknowledge that and to 
be, give the benefit of the doubt to the claimant. 
DR. ZIEMER:  Okay, additional comments or questions? 
 (no response) 
DR. ZIEMER:  Board members, are you ready to vote on this 































DR. WADE:  The Board supports the NIOSH proposal 
contained in TIB-012, rev. 1 and summarized in the draft 
“Federal Register” notice dated 1/6/06, concerning a new 
process for selecting dose reconstruction target organs 
for energy employees with a lymphoma cancer. 
DR. ZIEMER:  Are you ready to vote then on the motion? 
MS. MUNN:  It sounds a lot better than what I --
DR. ZIEMER:  I think he’s just quoting you there, Wanda. 
MS. MUNN:  That’s good. 
DR. ZIEMER:  Okay, we’ll vote by roll call. 
Lew, if you’ll give us a roll call, we’ll vote. 
DR. WADE:  Just give me a minute. Mr. Presley. 
MR. PRESLEY:  Yes. 
DR. WADE:  Mr. Gibson. 
MR. GIBSON:  Yes. 
DR. WADE:  Gen Roessler. 
DR. ROESSLER:  Yes. 
DR. WADE:  Dr. DeHart. 
DR. DeHART:  Yes. 
DR. WADE:  Wanda Munn. 
MS. MUNN:  Yes. 
DR. WADE:  Dr. Anderson. 
DR. ANDERSON:  Yes. 





























DR. MELIUS:  Yes. 

DR. WADE:  Mark Griffon. 

MR. GRIFFON:  Yes. 

DR. WADE:  Dr. Ziemer. 

DR. ZIEMER:  Yes. 

DR. WADE:  And I assume that Leon Owens and Richard 

Espinosa are not with us? 

 (no response) 
DR. ZIEMER:  Apparently not. 
DR. WADE:  Okay, then the motion is carried. 
DR. ZIEMER:  Motion carries. Thank you very much. 
MR. ELLIOTT:  Thank you. We appreciate this and the 
1,000 plus claimants that will benefit from this decision 
I think will be appreciative as well. 
WRAP UP, DR. PAUL ZIEMER, CHAIR
DR. ZIEMER:  Okay, we’re ready to wrap up. I think that 
we’ve efficiently covered the business for the day. I 
thank everybody for their time and input. 
Lew, do you have any final instructions for us in 
preparation for our next meeting? 
DR. WADE:  No, just rest, particularly Mark. But I think 
this worked well. I mean, I was worried about, you know, 
multiple issues, but I think we did our business well. 
We have to learn a little bit better how to practice the 





























sure that other people have our materials. But I mean, I 
thank you for your preparation, and I thank you for your 
patience through this call. And I look forward to seeing 
you all in Oak Ridge. 
MR. GRIFFON:  Can I ask one final thing, Paul? 
DR. ZIEMER:  You bet. 
MR. GRIFFON:  Do we have an agenda for the meeting yet? 
We might have one. I just might not have looked at it. 
DR. ZIEMER:  The only thing you have is Lew sent us a 
kind of a narrative memo earlier which outlined the 
business that would come before us at the Oak Ridge 
meeting. You can use that as a starting point. We know 
now that we will not be acting specifically on the Oak 
Ridge SEC petition, but we’ll be focusing again on the 
site profile. 
MR. GRIFFON:  Well, we have an opportunity to weigh in on 
the agenda items before it’s published? 
DR. ZIEMER:  Yeah, we can do that. 
And Lew, we can ask for input. 
DR. WADE:  What I’ll try and do, Mark, is to draft an 
agenda based upon what’s happened here today and get it 
to the Board by the end of this week and wouldn’t 
finalize that probably until the end of the following 
week. 





























feeling is that if we’re not going to take up the Y-12 

SEC petition evaluation, we may want to focus on some of 

the remaining tasks, the case reviews, the procedures 

reviews, et cetera. 





DR. ZIEMER:  Yes, and also, Jim, depending on where we 

are on the SEC procedures document, you may want to have 

your subcommittee meet as well, but you can determine 

that after you see what input you get. 

DR. WADE:  Yeah, Jim’s is a working group. 

DR. ZIEMER:  Or working group I meant. 





DR. ZIEMER:  Yes. 





DR. ZIEMER:  Right. 

DR. WADE:  Yes. 

DR. ROESSLER:  I’d like to ask a question of Bob Presley. 

Is there transportation from the Knoxville airport to Oak 

Ridge? 
MR. PRESLEY:  Yes, there is. It is hard to get. I would 
suggest --























MR. PRESLEY:  Yeah, that we can do. I would suggest that 

NIOSH let people try to come in, you know, when they can 

and pick some cars up because the one problem, too, that 

you’re going to have is once you get into Oak Ridge, is 

you’re going to just about have to go somewhere to eat. 

The restaurant in the hotel is all right. 





DR. ROESSLER: What hotel are we at? 

MR. PRESLEY:  You’re at the Doubletree which is the old 

Garden Plaza I understand. 

DR. ZIEMER:  Some of you will need to rent cars probably. 

Is there any other thing that needs to come before us or 

anything for the good of the order? 

 (no response) 
DR. ZIEMER:  If not, we stand adjourned. Thank you very 
much. 
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